PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/12, 15/62, C07K 13/00 C12N 5/10, C12Q 1/68 C07K 15/00	A1	(11) International Publication Number: WO 93/06215
		(43) International Publication Date: 1 April 1993 (01.04.93)

(21) International Application Number: PCT/US92/07570

(22) International Filing Date: 8 September 1992 (08.09.92)

(30) Priority data:
761,068 17 September 1991 (17.09.91) US

(71) Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 N. Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors: EVANS, Ronald, M. ; 8615 La Jolla Scenic Road N., La Jolla, Ca 92037 (US). MANGELSDORF, David, J. ; 4771 Seaford Place, San Diego, CA 92117 (US). ONG, Estelita, S. ; 6307 Hannon Court, San Diego, CA 92117 (US). ORO, Anthony, E. ; 10710 Escobar Drive, San Diego, CA 92124 (US). BORGMEYER, Uwe, K. ; Steilshooper Strasse 27, D-2000 Hamburg 60 (DE). GIGUERE, Vincent ; 1320 Islington Avenue, Apartment 606, Etobicoke, Ontario M9A 5C6 (CA). YAO, Tso-Pang ; 7564 Charmant Drive, Apartment 1838, San Diego, CA 92122 (US).

(74) Agent: REITER, Stephen, E.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: RECEPTOR OF THE THYROID/STEROID HORMONE RECEPTOR SUPERFAMILY

(57) Abstract

Novel members of the steroid/thyroid superfamily of receptors are described. DNA sequences encoding same, expression vectors containing such DNA and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel receptors of the invention, and various uses thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland			SE	Sweden
CI	Côte d'Ivoire	KR	Republic of Korea	SK	Slovak Republic
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CS	Czechoslovakia	LK	Sri Lanka	SU	Soviet Union
CZ	Czech Republic	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America

RECEPTOR OF THE THYROID/STEROID HORMONE RECEPTOR SUPERFAMILY

FIELD OF THE INVENTION

The present invention relates to novel steroid-hormone or steroid-hormone like receptor proteins, genes encoding such proteins, and methods of making and using such proteins. In a particular aspect, the present invention relates to bioassay systems for determining the selectivity of interaction between ligands and steroid-hormone or steroid-hormone like receptor proteins.

BACKGROUND OF THE INVENTION

Transcriptional regulation of development and homeostasis in complex eukaryotes, including humans and other mammals, birds, fish, insects, and the like, is controlled by a wide variety of regulatory substances, including steroid and thyroid hormones. These hormones exert potent effects on development and differentiation of phylogenetically diverse organisms. The effects of hormones are mediated by interaction with specific, high affinity binding proteins referred to as receptors.

The ability to identify additional compounds which are able to affect transcription of genes which are responsive to steroid hormones or metabolites thereof, would be of significant value in identifying compounds of potential therapeutic use. Further, systems useful for monitoring solutions, body fluids, and the like, for the presence of steroid hormones or metabolites thereof, would be of value in medical diagnosis, as well as for various biochemical applications.

A number of receptor proteins, each specific for one of several classes of cognate steroid hormones [e.g., estrogens (estrogen receptor), progesterones (progesterone

receptor), glucocorticoid (glucocorticoid receptor), androgens (androgen receptor), aldosterones (mineralocorticoid receptor), vitamin D (vitamin D receptor)], retinoids (e.g., retinoic acid receptor) or for cognate thyroid hormones (e.g., thyroid hormone receptor), are known. Receptor proteins have been found to be distributed throughout the cell population of complex eukaryotes in a tissue specific fashion.

Molecular cloning studies have made it possible to demonstrate that receptors for steroid, retinoid and thyroid hormones are all structurally related and comprise a superfamily of regulatory proteins. These regulatory proteins are capable of modulating specific gene expression in response to hormone stimulation by binding directly to cis-acting elements. Structural comparisons and functional studies with mutant receptors have revealed that these molecules are composed of a series of discrete functional domains, most notably, a DNA-binding domain that is composed typically of 66-68 amino acids, including two zinc fingers and an associated carboxy terminal stretch of approximately 250 amino acids, which latter region comprises the ligand-binding domain.

An important advance in the characterization of this superfamily of regulatory proteins has been the delineation of a growing list of gene products which possess the structural features of hormone receptors. This growing list of gene products has been isolated by low-stringency hybridization techniques employing DNA sequences encoding previously identified hormone receptor proteins.

It is known that steroid or thyroid hormones, protected forms thereof, or metabolites thereof, enter cells and bind to the corresponding specific receptor protein, initiating an allosteric alteration of the

protein. As a result of this alteration, the complex of receptor and hormone (or metabolite thereof) is capable of binding to certain specific sites on chromatin with high affinity.

It is also known that many of the primary effects of steroid and thyroid hormones involve increased transcription of a subset of genes in specific cell types.

A number of steroid hormone- and thyroid hormone-responsive transcriptional control units have been identified. These include the mouse mammary tumor virus 5'-long terminal repeat (MTV LTR), responsive to glucocorticoid, aldosterone and androgen hormones; the transcriptional control units for mammalian growth hormone genes, responsive to glucocorticoids, estrogens and thyroid hormones; the transcriptional control units for mammalian prolactin genes and progesterone receptor genes, responsive to estrogens; the transcriptional control units for avian ovalbumin genes, responsive to progesterones; mammalian metallothionein gene transcriptional control units, responsive to glucocorticoids; and mammalian hepatic α_{2u}-globulin gene transcriptional control units, responsive to androgens, estrogens, thyroid hormones, and glucocorticoids.

A major obstacle to further understanding and more widespread use of the various members of the steroid/thyroid superfamily of hormone receptors has been a lack of availability of the receptor proteins, in sufficient quantity and sufficiently pure form, to allow them to be adequately characterized. The same is true for the DNA gene segments which encode them. Lack of availability of these DNA segments has prevented <u>in vitro</u> manipulation and <u>in vivo</u> expression of the receptor-

encoding genes, and consequently the knowledge such manipulation and expression would yield.

In addition, a further obstacle to a more complete understanding and more widespread use of members of the steroid/thyroid receptor superfamily is the fact that additional members of this superfamily remain to be discovered, isolated and characterized.

The present invention is directed to overcoming these problems of short supply of adequately purified receptor material, lack of DNA segments which encode such receptors and increasing the number of identified and characterized hormone receptors which are available for use.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have discovered novel members of the steroid/thyroid superfamily of receptors. The novel receptors of the present invention are soluble, intracellular, nuclear (as opposed to cell surface) receptors, which are activated to modulate transcription of certain genes in animal cells when the cells are exposed to ligands therefor. The nuclear receptors of the present invention differ significantly from known steroid receptors, both in primary sequence and in responsiveness to exposure of cells to various ligands, e.g., steroids or steroid-like compounds.

Also provided in accordance with the present invention are DNAs encoding the receptors of the present invention, including expression vectors for expression thereof in animal cells, cells transformed with such expression vectors, cells co-transformed with such expression vectors and reporter vectors (to monitor the

ability of the receptors to modulate transcription when the cells are exposed to a compound which interacts with the receptor); and methods of using such co-transformed cells in screening for compounds which are capable of leading to modulation of receptor activity.

Further provided in accordance with the present invention are DNA and RNA probes for identifying DNAs encoding additional steroid receptors.

In accordance with yet another embodiment of the invention, there is provided a method for making the receptors of the invention by expressing DNAs which encode the receptors in suitable host organisms.

The novel receptors and DNAs encoding same can be employed for a variety of purposes. For example, novel receptors of the present invention can be included as part of a panel of receptors which are screened to determine the selectivity of interaction of proposed agonists or antagonists and other receptors. Thus, a compound which is believed to interact selectively, for example, with the glucocorticoid receptor, should not have any substantial effect on any other receptors, including those of the present invention. Conversely, if such a proposed compound does interact with one or more of the invention receptors, then the possibility of side reactions caused by such compound is clearly indicated.

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 is a schematic diagram correlating the relationship between the alternate spliced variants of invention receptor XR1.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided DNAs encoding a polypeptide characterized by having a DNA binding domain comprising about 66 amino acids with 9 cysteine (Cys) residues, wherein said DNA binding domain has:

(i) less than about 70% amino acid sequence identity with the DNA binding domain of human retinoic acid receptor-alpha (hRAR-alpha);

(ii) less than about 60% amino acid sequence identity with the DNA binding domain of human thyroid receptor-beta (hTR-beta);

(iii) less than about 50% amino acid sequence identity with the DNA binding domain of human glucocorticoid receptor (hGR); and

(iv) less than about 65% amino acid sequence identity in with the DNA binding domain of human retinoid X receptor-alpha (hRXR-alpha).

Alternatively, DNAs of the invention can be characterized with respect to percent amino acid sequence identity of the ligand binding domain of polypeptides encoded thereby, relative to amino acid sequences of previously characterized receptors. As yet another alternative, DNAs of the invention can be characterized by the percent overall amino acid sequence identity of polypeptides encoded thereby, relative to amino acid sequences of previously characterized receptors.

Thus, DNAs of the invention can be characterized as encoding polypeptides having, in the ligand binding domain:

(i) less than about 35% amino acid sequence identity with the ligand binding domain of hRAR-alpha;

(ii) less than about 30% amino acid sequence identity with the ligand binding domain of hTR-beta;

(iii) less than about 25% amino acid sequence identity with the ligand binding domain of hGR; and

(iv) less than about 30% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

DNAs of the invention can be further characterized as encoding polypeptides having an overall amino acid sequence identity of:

(i) less than about 35% relative to hRAR-alpha;

(ii) less than about 35% relative to hTR-beta;

(iii) less than about 25% relative to hGR; and

(iv) less than about 35% relative to hRXR-alpha.

Specific receptors contemplated for use in the practice of the present invention include:

"XR1" (variously referred to herein as receptor "XR1", "hXR1", "hXR1.pep" or "verHT19.pep"; wherein the prefix "h" indicates the clone is of human origin), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 68% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 59% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 45% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 2 for a specific amino acid sequence representative of XR1, as well as Sequence ID No. 1 which is an exemplary nucleotide sequence encoding XR1. In addition, Sequence ID Nos. 4 and 6 present alternate amino terminal sequences for the clone referred to as XR1 (the variant referred to as verht3 is presented in Sequence ID No. 4 (an exemplary nucleotide sequence encoding such variant presented in Sequence ID No. 3), and the variant referred to as verhr5 is presented in Sequence ID No. 6 (an exemplary nucleotide sequence encoding such variant presented in Sequence ID No. 5);

"XR2" (variously referred to herein as receptor "XR2", "hXR2" or "hXR2.pep"), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 55% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 56% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 52% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 8 for a specific amino acid sequence representative of XR2, as well as Sequence ID No. 7 which is an exemplary nucleotide sequence encoding XR2;

"XR4" (variously referred to herein as receptor "XR4", "mXR4" or "mXR4.pep"; wherein the prefix "m" indicates the clone is of mouse origin), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 62% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 58% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 48% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 62% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 10 for a specific amino acid sequence representative of XR4, as well as Sequence ID No. 9 which is an exemplary nucleotide sequence encoding XR4;

"XR5" (variously referred to herein as receptor "XR5", "mXR5" or "mXR5.pep"), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 52% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 44% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 61% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 12 for a specific amino acid sequence representative of XR5, as well as Sequence ID No. 11 which is an exemplary nucleotide sequence encoding XR5; and

"XR79" (variously referred to herein as "XR79", "dXR79" or "dXR79.pep"; wherein the prefix "d" indicates the clone is of Drosophila origin), a polypeptide characterized as having a DNA binding domain comprising:

(i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 55% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha;

see also Sequence ID No. 14 for a specific amino acid sequence representative of XR79, as well as Sequence ID No. 13 which is an exemplary nucleotide sequence encoding XR79.

The receptor referred to herein as "XR1" is observed as three closely related proteins, presumably

produced by alternate splicing from a single gene. The first of these proteins to be characterized (referred to as "verht19") comprises about 548 amino acids, and has a M_r of about 63 kilodalton. Northern analysis indicates that a single mRNA species corresponding to XR1 is highly expressed in the brain. A variant of verht19 (alternatively referred to as "verht3", XR1' or XR1prime) is further characterized as comprising about 556 amino acids, and having a M_r of about 64 kilodalton. Yet another variant of verht19 (alternatively referred to as "verhr5", XR1'' or XR1prim2) is further characterized as comprising about 523 amino acids, and having a M_r of about 60 kilodalton. The interrelationship between these three variants of XR1 is illustrated schematically in Figure 1.

The receptor referred to herein as "XR2" is further characterized as a protein comprising about 440 amino acids, and having a M_r of about 50 kilodalton. Northern analysis indicates that a single mRNA species (~1.7 kb) corresponding to XR2 is expressed most highly in liver, kidney, lung, intestine and adrenals of adult male rats. Transactivation studies (employing chimeric receptors containing the XR2 DNA binding domain and the ligand binding domain of a prior art receptor) indicate that XR2 is capable of binding to TRE_{pal}. In terms of amino acid sequence identity with prior art receptors, XR2 is most closely related to the vitamin D receptor (39% overall amino acid sequence identity, 17% amino acid identity in the amino terminal domain of the receptor, 53% amino acid identity in the DNA binding domain of the receptor and 37% amino acid identity in the ligand binding domain of the receptor).

The receptor referred to herein as "XR4" is further characterized as a protein comprising about 439 amino acids, and having a M_r of about 50 kilodalton. In

terms of amino acid sequence identity with prior art receptors, XR4 is most closely related to the peroxisome proliferator-activated receptor (62% overall amino acid sequence identity, 30% amino acid identity in the amino terminal domain of the receptor, 86% amino acid identity in the DNA binding domain of the receptor and 64% amino acid identity in the ligand binding domain of the receptor). XR4 is expressed ubiquitously and throughout development (as determined by in situ hybridization).

The receptor referred to herein as "XR5" is further characterized as a protein comprising about 556 amino acids, and having a M_r of about 64 kilodalton. In situ hybridization reveals widespread expression throughout development. High levels of expression are observed in the embryonic liver around day 12, indicating a potential role in haematopoiesis. High levels are also found in maturing dorsal root ganglia and in the skin. In terms of amino acid sequence identity with prior art receptors, XR5 is most closely related to the rat nerve growth factor induced protein-B (NGFI-B) receptor. With respect to NGFI-B, XR5 has 29% overall amino acid sequence identity, 15% amino acid identity in the amino terminal domain of the receptor, 52% amino acid identity in the DNA binding domain of the receptor and 29% amino acid identity in the ligand binding domain of the receptor.

The receptor referred to herein as "XR79" is further characterized as a protein comprising about 601 amino acids, and having a M_r of about 66 kilodalton. Whole mount in situ hybridization reveals a fairly uniform pattern of RNA expression during embryogenesis. Northern blot analysis indicates that a 2.5 kb transcript corresponding to XR79 is present in RNA throughout development. The levels of XR79 mRNA are highest in RNA from 0 - 3 hour old embryos, i.e., maternal product, and

lowest in RNA from the second instar larvae (L2 stage). In situ hybridization reveals that XR79 is distributed relatively uniformly at different stages of embryogenesis. In terms of amino acid sequence identity with prior art receptors, XR79 is most closely related to the mammalian receptor TR2 [see Chang and Kokontis in Biochemical and Biophysical Research Communications 155: 971-977 (1988)], as well as members of the coup family, i.e., ear2, coup(ear3), harp-1. With respect to TR2, XR79 has 33% overall amino acid sequence identity, 16% amino acid identity in the amino terminal domain of the receptor, 74% amino acid identity in the DNA binding domain of the receptor and 28% amino acid identity in the ligand binding domain of the receptor. With respect to coup (ear3) [see Miyajima et al., in Nucl Acids Res 16: 11057-11074 (1988)], XR79 has 32% overall amino acid sequence identity, 21% amino acid identity in the amino terminal domain of the receptor, 62% amino acid identity in the DNA binding domain of the receptor and 22% amino acid identity in the ligand binding domain of the receptor.

In accordance with a specific embodiment of the present invention, there is provided an expression vector which comprises DNA as previously described (or functional fragments thereof), and which further comprises:

at the 5'-end of said DNA, a promoter and a nucleotide triplet encoding a translational start codon, and

at the 3'-end of said DNA, a nucleotide triplet encoding a translational stop codon;

wherein said expression vector is operative in a cell in culture (e.g., yeast, bacteria, mammalian) to express the protein encoded by said DNA.

As employed herein, reference to "functional fragments" embraces DNA encoding portions of the invention

receptors which retain one or more of the functional characteristics of steroid hormone or steroid hormone-like receptors, e.g., DNA binding properties of such receptors, ligand binding properties of such receptors, the ability to heterodimerize, nuclear localization properties of such receptors, phosphorylation properties of such receptors, transactivation domains characteristic of such receptors, and the like.

In accordance with a further embodiment of the present invention, there are provided cells in culture (e.g., yeast, bacteria, mammalian) which are transformed with the above-described expression vector.

In accordance with yet another embodiment of the present invention, there is provided a method of making the above-described novel receptors (or functional fragments thereof) by culturing the above-described cells under conditions suitable for expression of polypeptide product.

In accordance with a further embodiment of the present invention, there are provided novel polypeptide products produced by the above-described method.

In accordance with a still further embodiment of the present invention, there are provided chimeric receptors comprising at least an amino-terminal domain, a DNA-binding domain, and a ligand-binding domain,

wherein at least one of the domains thereof is derived from the novel polypeptides of the present invention; and

wherein at least one of the domains thereof is derived from at least one previously identified member of the steroid/thyroid superfamily of receptors e.g., glucocorticoid receptor (GR), thyroid receptors (TR), retinoic

acid receptors (RAR), mineralocorticoid receptor (MR), estrogen receptor (ER), the estrogen related receptors (e.g., hERR1 or hERR2), retinoid X receptors (e.g., RXRα, RXRβ or RXRδ), vitamin D receptor (VDR), aldosterone receptor (AR), progesterone receptor (PR), the ultraspiracle receptor (USP), nerve growth factor induced protein-B (NGFI-B), the coup family of transcription factors (COUP), peroxisome proliferator-activated receptor (PPAR), mammalian receptor TR2 (TR2), and the like.

In accordance with yet another embodiment of the present invention, there is provided a method of using polypeptides of the invention to screen for response elements and/or ligands for the novel receptors described herein. The method to identify compounds which act as ligands for receptor polypeptides of the invention comprising:

assaying for the presence or absence of reporter protein upon contacting of cells containing a chimeric form of said receptor polypeptide and reporter vector with said compound;

wherein said chimeric form of said receptor polypeptide comprises the ligand binding domain of said receptor polypeptide and the amino-terminal and DNA-binding domains of one or more previously identified members of the steroid/thyroid superfamily of receptors;

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element which is responsive to the receptor from which the DNA-binding domain of said chimeric form of said receptor polypeptide is derived, and

(c) a DNA segment encoding a reporter protein,

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof, and thereafter

identifying those compounds which induce or block the production of reporter in the presence of said chimeric form of said receptor polypeptide.

The method to identify response elements for receptor polypeptides of the invention comprises:

assaying for the presence or absence of reporter protein upon contacting of cells containing a chimeric form of said receptor polypeptide and reporter vector with a compound which is a known agonist or antagonist for the receptor from which the ligand-binding domain of said chimeric form of said receptor polypeptide is derived;

wherein said chimeric form of said receptor polypeptide comprises the DNA-binding domain of the receptor polypeptide and the amino-terminal and ligand-binding domains of one or more previously identified members of the steroid/thyroid superfamily of receptors;

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a putative hormone response element, and

(c) a DNA segment encoding a reporter protein,

wherein said reporter protein-encoding DNA segment is operatively

linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof; and

identifying those response elements for which the production of reporter is induced or blocked in the presence of said chimeric form of said receptor polypeptide.

In accordance with yet another embodiment of the present invention, there is provided a DNA or RNA labeled for detection; wherein said DNA or RNA comprises a nucleic acid segment, preferably of at least 20 bases in length, wherein said segment has substantially the same sequence as a segment of the same length selected from the DNA segment represented by bases 21 -1902, inclusive, of Sequence ID No. 1, bases 1 - 386, inclusive, of Sequence ID No. 3, bases 10 - 300, inclusive, of Sequence ID No. 5, bases 21 - 1615, inclusive, of Sequence ID No. 7, bases 21 - 2000, inclusive, of Sequence ID No. 9, bases 1 - 2450, inclusive, of Sequence ID No. 11, bases 21 - 2295, inclusive, of Sequence ID No. 13, or the complement of any of said segments.

In accordance with still another embodiment of the present invention, there are provided methods of testing compound(s) for the ability to regulate transcription-activating effects of a receptor polypeptide, said method comprising assaying for the presence or absence of reporter protein upon contacting of cells containing a receptor polypeptide and reporter vector with said compound;

wherein said receptor polypeptide is characterized by having a DNA binding domain comprising

about 66 amino acids with 9 Cys residues, wherein said DNA binding domain has:

(i) less than about 70% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) less than about 60% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) less than about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) less than about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha; and

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element, and

(c) a DNA segment encoding a reporter protein,

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof.

In accordance with a still further embodiment of the present invention, there is provided a method of testing a compound for its ability to selectively regulate the transcription-activating effects of a specific receptor polypeptide, said method comprising:

assaying for the presence or absence of reporter protein upon contacting of cells containing said receptor polypeptide and reporter vector with said compound;

wherein said receptor polypeptide is characterized by being responsive to the presence of a known ligand for said receptor to regulate the transcription of associated gene(s);

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element, and

(c) a DNA segment encoding a reporter protein,

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof; and

assaying for the presence or absence of reporter protein upon contacting of cells containing chimeric receptor polypeptide and reporter vector with said compound;

wherein said chimeric receptor polypeptide comprises the ligand binding domain of a novel receptor of the present invention, and the DNA binding domain of said specific receptor; and thereafter

selecting those compounds which induce or block the production of reporter in the presence of said specific receptor, but are substantially unable to induce or block the production of reporter in the presence of said chimeric receptor.

The above-described methods of testing compounds for the ability to regulate transcription-activating effects of invention receptor polypeptides can be carried out employing methods described in USSN 108,471, filed October 20, 1987, the entire contents of which are hereby incorporated by reference herein.

As employed herein, the term "expression vector" refers to constructs containing DNA of the invention (or functional fragments thereof), plus all sequences necessary for manipulation and expression of such DNA. Such an expression vector will contain both a "translational start site" and a "translational stop site". Those of skill in the art can readily identify sequences which act as either translational start sites or translational stop sites.

Suitable host cells for use in the practice of the present invention include prokaroytic and eukaryote cells, e.g., bacteria, yeast, mammalian cells and the like.

Labeled DNA or RNA contemplated for use in the practice of the present invention comprises nucleic acid sequences covalently attached to readily analyzable species such as, for example, radiolabel (e.g., ^{32}P, ^{3}H, ^{35}S, and the like), enzymatically active label, and the like.

The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLES

EXAMPLE I
ISOLATION AND CHARACTERIZATION OF XR1

The KpnI/SacI restriction fragment (503bp) including the DNA-binding domain of hRAR-alpha-encoding DNA [See Giguere et al., Nature 330: 624-629 (1987); and commonly assigned United States Patent Application Serial No. 276,536, filed November 30, 1988; and European Patent Application Publication No. 0 325 849, all incorporated herein by reference] was nick-translated and used to screen a rat brain cDNA library [see DNA Cloning, A practical approach, Vol I and II, D. M. Glover, ed. (IRL Press

(1985)] and a lambda-gt11 human liver cDNA library [Kwok et al., Biochem. 24: 556 (1985)] at low stringency. The hybridization mixture contained 35% formamide, 1X Denhardt's, 5X SSPE (1X SSPE=0.15 M NaCl, 10mM Na_2HPO_4 1mM EDTA), 0.1% SDS, 10% dextran sulfate, 100 μg/ml denatured salmon sperm DNA and 10^6 cpm of [^{32}P]-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42°C, washed once at 25°C for 15 min with 2X SSC (1X SSC=0.15 M NaCl, 0.015 M sodium citrate), 0.1% SDS and then washed twice at 55°C for 30 min. in 2X SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70°C using an intensifying screen.

After several rounds of screening, a pure positive clone having an insert of about 2.1 kb is obtained from the rat brain cDNA library. Several positive clones are obtained from the human liver library. Sequence analysis of the positive rat brain clone indicates that this clone encodes a novel member of the steroid/thyroid superfamily of receptors. Sequence analysis of one of the positive human liver clones (designated "hL1", a 1.7 kb cDNA) indicates that this clone is the human equivalent of the rat brain clone, based on sequence homology.

The EcoRI insert of clone hL1 (labeled with ^{32}P) is also used as a probe to screen a human testis cDNA library (Clonetech) and a human retina cDNA library [see Nathans et al., in Science 232: 193-202 (1986)]. Hybridization conditions comprised a hybridization mixture containing 50% formamide, 1X Denhardt's, 5X SSPE, 0.1% SDS, 100 μg/ml denatured salmon sperm DNA and 10^6 cpm of [^{32}P]-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42°C, washed once at 25°C for 15 min with 2X SSC (1X SSC=0.15 M NaCl, 0.015 M sodium citrate), 0.1% SDS and then washed twice at 55°C for 30 min. in 2X

SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70°C using an intensifying screen.

After several rounds of screening, five (5) positive clones were obtained from the human retina cDNA library, and five (5) positive clones were obtained from the human testis cDNA library. Sequence analysis of two clones from the testis library indicates that these clones encode different isoforms of the same novel member of the steroid/thyroid superfamily of receptors (designated as "Verht19" and "Verht3"). Sequence analysis of one of the positive clones from the human retina library indicates that this clone is yet another isoform of the same novel member of the steroid/thyroid superfamily of receptors (designated "Verhr5"). The full length sequence of Verht19 is set forth herein as Sequence ID No. 1 (which includes an indication of where the splice site is for each of the variants, verht3 and verhr5). The amino-terminal sequence of verht3 and verhr5 are presented in Sequence ID Nos. 3 and 5, respectively. In addition, the interrelationship between each of these three isoforms is illustrated schematically in Figure 1.

EXAMPLE II

ISOLATION AND CHARACTERIZATION OF XR2

The KpnI/SacI restriction fragment (503bp) including the DNA-binding domain of hRAR-alpha-encoding DNA [See Giguere et al., Nature 330: 624 (1987); and commonly assigned United States Patent Application Serial No. 276,536, filed November 30, 1988; and European Patent Application Publication No. 0 325 849, all incorporated herein by reference] was nick-translated and used to screen a lambda-gt11 human liver cDNA library [Kwok et al.,Biochem. 24: 556 (1985)] at low stringency. The hybridization mixture contained 35% formamide, 1X

Denhardt's, 5X SSPE (1X SSPE=0.15 M NaCl, 10mM Na_2HPO_4 1mM EDTA), 0.1% SDS, 10% dextran sulfate, 100 mg/ml denatured salmon sperm DNA and 10^6 cpm of [^{32}P]-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42°C, washed once at 25°C for 15 min with 2X SSC (1X SSC=0.15 M NaCl, 0.015 M sodium citrate), 0.1% SDS and then washed twice at 55°C for 30 min. in 2X SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70°C using an intensifying screen.

Positive clones were isolated, subcloned into pGEM vectors (Promega, Madison, Wisconsin, USA), restriction mapped, and re-subcloned in various sized restriction fragments into M13mp18 and M13mp19 sequencing vectors. DNA sequence was determined by the dideoxy method with Sequenase™ sequencing kit (United States Biochemical, Cleveland, Ohio, USA) and analyzed by University of Wisconsin Genetics Computer Group programs [Devereux et al., Nucl. Acids Res. 12, 387 (1984)]. Several clones of a unique receptor-like sequence were identified, the longest of which was designated lambda-HL1-1 (also referred to herein as XR2).

The DNA sequence of the resulting clone is set forth as Sequence ID No. 7.

EXAMPLE III
ISOLATION AND CHARACTERIZATION OF XR4

A clone which encodes a portion of the coding sequence for XR4 was isolated from a mouse embryonic library by screening under low stringency conditions (as described above).

The library used was a lambda gt10 day 8.5 cDNA library having an approximate titer of 1.3 x 10^{10}/ml

(derived from 8.5 day old embryonic material with as much of the amnion and extraembryonic tissues dissected away as possible). This library was prepared from poly A^+ selected RNA (by oligo-dT priming), Gubler & Hoffman cloning methods [Gene 25: 263 (1983)], and cloned into the EcoRI site of lambda gt10.

The probe used was a mixture of radioactively labeled DNA derived from the DNA binding regions of the human alpha and beta retinoic acid receptors.

Positive clones were isolated, subcloned into pGEM vectors (Promega, Madison, Wisconsin, USA), restriction mapped, and re-subcloned in various sized restriction fragments into M13mp18 and M13mp19 sequencing vectors. DNA sequence was determined by the dideoxy method with Sequenase™ sequencing kit (United States Biochemical, Cleveland, Ohio, USA) and analyzed by University of Wisconsin Genetics Computer Group programs [Devereux et al., Nucl. Acids Res. 12, 387 (1984)]. Several clones of a unique receptor-like sequence were identified, the longest of which was designated XR4.

The DNA sequence of the resulting clone is set forth as Sequence ID No. 9.

EXAMPLE IV
ISOLATION AND CHARACTERIZATION OF XR5

A clone which encodes a portion of the coding sequence for XR5 was isolated from a mouse embryonic library by screening under low stringency conditions (as described above).

The library used was the same lambda gt10 day 8.5 cDNA library described in the preceding example.

Similarly, the probe used was the same mixture of radioactively labeled DNA described in the preceding example.

Only one of the clones isolated corresponds to a portion of the coding region for XR5. A 0.7 kb EcoRI fragment of this clone (designated as No. II-17) was subcloned into the bluescript pksII-Vector. Partial sequence analysis of this insert fragment shows homology to the DNA binding domain of the retinoic acid receptors.

The EcoRI-insert was used to rescreen a second library (a mouse lambda ZAPII day 6.5 cDNA library, prepared as described below) under high stringency conditions. A total of 21 phages were isolated and rescued into the psk-vector. Partial sequencing allowed inserts from 13 of these phages to be identified as having sequences which overlap with XR5 II-17. The clone with the longest single EcoRI-insert was sequenced, revealing an open reading frame of 556 amino acids. This sequence was extended further upstream by 9bp from the furthest 5'-reaching clone.

The DNA sequence of the resulting clone is set forth as Sequence ID No. 11.

The day 6.5 cDNA library, derived from 6.5 day old mouse embryonic material was prepared from poly A^+ selected RNA (by oligo-dT priming), and cloned into the EcoRI site of lambda gt10.

EXAMPLE V

ISOLATION AND CHARACTERIZATION OF XR79

The 550 bp BamHI restriction fragment, including the DNA-binding domain of mouse RAR-beta-encoding DNA (See

Hamada et al., Proc. Natl. Acad. Sci. 86: 8289 (1989); incorporated by reference herein) was nick-translated and used to screen a Lambda-ZAP cDNA library comprising a size selected Drosophila genomic library (~2-5 kb, EcoRI restricted) at low stringency. The hybridization mixture contained 35% formamide, 1X Denhardt's, 5X SSPE (1X SSPE=0.15 M NaCl, 10mM Na_2HPO_4 1mM EDTA), 0.1% SDS, 10% dextran sulfate, 100 mg/ml denatured salmon sperm DNA and 10^6 cpm of [^{32}P]-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42°C, washed once at 25°C for 15 min with 2X SSC (1X SSC=0.15 M NaCl, 0.015 M sodium citrate), 0.1% SDS and then washed twice at 55°C for 30 min. in 2X SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70°C using an intensifying screen.

After several rounds of screening, a pure positive clone having an insert of about 3.5 kb is obtained from the Drosophila genomic library. This genomic clone was then used to screen a Drosophila imaginal disc lambda gt10 cDNA library [obtained from Dr. Charles Zuker; see DNA Cloning, A practical approach, Vol I and II, D. M. Glover, ed. (IRL Press (1985)]. Hybridization conditions comprised a hybridization mixture containing 50% formamide, 1X Denhardt's, 5X SSPE, 0.1% SDS, 100 μg/ml denatured salmon sperm DNA and 10^6 cpm of [^{32}P]-labelled probe. Duplicate nitrocellulose filters were hybridized for 16h at 42°C, washed once at 25°C for 15 min with 2X SSC (1X SSC=0.15 M NaCl, 0.015 M sodium citrate), 0.1% SDS and then washed twice at 55°C for 30 min. in 2X SSC, 0.1% SDS. The filters were autoradiographed for 3 days at -70°C using an intensifying screen.

Sequence analysis of the positive cDNA clone indicates that this clone encodes another novel member of the steroid/thyroid superfamily of receptors (designated

"XR79", a 2.5 kb cDNA). See Sequence ID No. 13 for the DNA sequence of the resulting clone.

The 2.5 kb cDNA encoding XR79 was nick-translated and used as a probe for a nitrocellulose filter containing size-fractionated total RNA, isolated by standard methods from Drosophila melanogaster of different developmental stages. The probe hybridized to a 2.5 kb transcript which was present in RNA throughout development. The levels were highest in RNA from 0 - 3 hour old embryos and lowest in RNA from second instar larvae. The same 2.5 kb cDNA was nick translated using biotinylated nucleotides and used as a probe for in situ sybridization to whole Drosophila embryos [Tautz and Pfeifle, Chromosoma 98: 81-85 (1989)]. The RNA distribution appeared relatively uniform at different stages of embryogenesis.

EXAMPLE VI
SEQUENCE COMPARISONS OF INVENTION RECEPTORS WITH hRARα, hTRß, hGR, AND hRXRα

Amino acid sequences of XR1, hRAR-alpha (human retinoic acid receptor-alpha), hTR-beta (human thyroid hormone receptor-beta), hGR (human glucocorticoid receptor), and hRXR-alpha (human retinoid receptor-alpha) were aligned using the University of Wisconsin Genetics Computer Group program "Bestfit" (Devereux et al., supra). The percentage of amino acid identity between RX2 and the other receptors, i.e., in the 66 - 68 amino acid DNA binding domains and the ligand-binding domains, are summarized in Table 1 as percent amino acid identity.

TABLE 1
Percent amino acid identity between
receptor XR1 (verht19) and hRARα, TRß, hGR, and hRXRα

Comparison receptor	Percent amino acid identity			
	Overall	N-term[1]	DNA-BD[2]	Ligand-BD[3]
hGR	18	21	45	20
hTRß	31	14	59	30
hRARα	32	25	68	27
hRXRα	29	15	65	22

[1]"N-term" = amino terminal domain
[2]"DNA-BD" = receptor DNA binding domain
[3]"Ligand-BD" = receptor ligand binding domain

Similarly, the amino acid sequences of invention receptors XR2, XR4, XR5, and XR79 were compared with human RAR-alpha (hRARα), human TR-beta (hTRβ), human glucocorticoid (hGR) and human RXR-alpha (hRXRα). As done in Table 1, the percentage of amino acid identity between the invention receptors and the other receptors are summarized in Tables 2 - 5, respectively.

TABLE 2
Percent amino acid identity between
receptor XR2 and hRARα, TRß, hGR, and hRXRα

Comparison receptor	Percent amino acid identity			
	Overall	N-term[1]	DNA-BD[2]	Ligand-BD[3]
hGR	24	21	50	20
hTRß	31	19	56	29
hRARα	33	21	55	32
hRXRα	27	19	52	23

[1]"N-term" = amino terminal domain
[2]"DNA-BD" = receptor DNA binding domain
[3]"Ligand-BD" = receptor ligand binding domain

TABLE 3
Percent amino acid identity between
receptor XR4 and hRARα, TRβ, hGR, and hRXRα

Comparison receptor	Percent amino acid identity			
	Overall	N-term[1]	DNA-BD[2]	Ligand-BD[3]
hGR	25	24	48	21
hTRβ	31	21	58	27
hRARα	32	22	62	29
hRXRα	33	24	62	28

[1]"N-term" = amino terminal domain
[1]"DNA-BD" = receptor DNA binding domain
[2]"Ligand-BD" = receptor ligand binding domain

TABLE 4
Percent amino acid identity between
receptor XR5 and hRARα, TRβ, hGR, and hRXRα

Comparison receptor	Percent amino acid identity			
	Overall	N-term[1]	DNA-BD[2]	Ligand-BD[3]
hGR	20	20	44	20
hTRβ	24	14	52	22
hRARα	27	19	59	19
hRXRα	29	17	61	27

[1]"N-term" = amino terminal domain
[2]"DNA-BD" = receptor DNA binding domain
[3]"Ligand-BD" = receptor ligand binding domain

TABLE 5
Percent amino acid identity between
receptor XR79 and hRARα, TRß, hGR, and hRXRα

Comparison receptor	Percent amino acid identity			
	Overall	N-term[1]	DNA-BD[2]	Ligand-BD[3]
hGR	18	22	50	20
hTRß	28	22	55	20
hRARα	24	14	59	18
hRXRα	33	20	65	24

[1]"N-term" = amino terminal domain
[2]"DNA-BD" = receptor DNA binding domain
[3]"Ligand-BD" = receptor ligand binding domain

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

SUMMARY OF SEQUENCES

Sequence ID No. 1 is a nucleotide sequence encoding novel receptor of the present invention designated as "hXR1".

Sequence ID No. 2 is the amino acid sequence deduced from the nucleotide sequence set forth in Sequence ID No. 1 (variously referred to herein as receptor "XR1", "hXR1", "hXR1.pep" or "verHT19.pep").

Sequence ID No. 3 is a nucleotide sequence encoding the amino-terminal portion of the novel receptor of the present invention designated as "hXR1prime".

Sequence ID No. 4 is the amino acid sequence deduced from the nucleotide sequence set forth in Sequence ID No. 3 (variously referred to herein as receptor "XR1prime", "hXR1prime", "hXR1prime.pep" or "verHT3.pep").

Sequence ID No. 5 is a nucleotide sequence encoding the amino-terminal portion of the novel receptor of the present invention designated as "hXR1prim2".

Sequence ID No. 6 is the amino acid sequence deduced from the nucleotide sequence set forth in Sequence ID No. 5 (variously referred to herein as receptor "XR1prim2", "hXR1prim2", "hXR1prim2.pep" or "verHr5.pep").

Sequence ID No. 7 is a nucleotide sequence encoding the novel receptor of the present invention designated as "hXR2".

Sequence ID No. 8 is the amino acid sequence deduced from the nucleotide sequence set forth in Sequence

ID No. 7 (variously referred to herein as receptor "XR2", "hXR2" or "hXR2.pep").

Sequence ID No. 9 is a nucleotide sequence encoding novel receptor of the present invention referred to herein as "mXR4".

Sequence ID No. 10 is the amino acid sequence deduced from the nucleotide sequence of Sequence ID No. 9 (variously referred to herein as receptor "XR4", "mXR4" or "mXR4.pep").

Sequence ID No. 11 is the nucleotide sequence encoding the novel receptor of the present invention referred to as "mXR5".

Sequence ID No. 12 is the amino acid sequence deduced from the nucleotide sequence of Sequence ID No. 11 (variously referred to herein as receptor "XR5", "mXR5" or "mXR5.pep").

Sequence ID No. 13 is the nucleotide sequence encoding the novel receptor of the present invention referred to as "dXR79".

Sequence ID No. 14 is the amino acid sequence deduced from the nucleotide sequence of Sequence ID No. 13 (variously referred to herein as "XR79", "dXR79" or "dXR79.pep").

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: EVANS Ph.D., RONALD M.
MANGELSDORF Ph.D., DAVID J.
ONG Ms., ESTELITA S.
ORO Ph.D., ANTHONY E.
BORGMEYER Ph.D., UWE K.
GIGUERE Ph.D., VINCENT NMN
YAO Mr., TSO-PANG NMN

(ii) TITLE OF INVENTION: NOVEL RECEPTORS

(iii) NUMBER OF SEQUENCES: 14

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
(B) STREET: 444 So. Flower St., Suite 2000
(C) CITY: Los Angeles
(D) STATE: CA
(E) COUNTRY: US
(F) ZIP: 90071-2921

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Reiter Ph.D., Stephen E.
(B) REGISTRATION NUMBER: 31192
(C) REFERENCE/DOCKET NUMBER: P31 8936

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (619) 535-9001
(B) TELEFAX: (619) 535-8949

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1952 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: XR1 (VERHT19.SEQ)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 79..1725

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 349..1952
(D) OTHER INFORMATION: /product= "Carboxy terminal portion of XR1 variant verht3"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 352..1952
(D) OTHER INFORMATION: /product= "Carboxy terminal portion of XR1 variant verhr5"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GAATTCGGGG ACTCCATAGT ACACTGGGGC AAAGCACAGC CCCAGTTTCT GGAGGCAGAT      60

GGGTAACCAG GAAAAGGC ATG AAT GAG GGG GCC CCA GGA GAC AGT GAC TTA      111
                    Met Asn Glu Gly Ala Pro Gly Asp Ser Asp Leu
                      1               5                  10

GAG ACT GAG GCA AGA GTG CCG TGG TCA ATC ATG GGT CAT TGT CTT CGA      159
Glu Thr Glu Ala Arg Val Pro Trp Ser Ile Met Gly His Cys Leu Arg
            15                  20                  25

ACT GGA CAG GCC AGA ATG TCT GCC ACA CCC ACA CCT GCA GGT GAA GGA      207
Thr Gly Gln Ala Arg Met Ser Ala Thr Pro Thr Pro Ala Gly Glu Gly
        30                  35                  40

GCC AGA AGC TCT TCA ACC TGT AGC TCC CTG AGC AGG CTG TTC TGG TCT      255
Ala Arg Ser Ser Ser Thr Cys Ser Ser Leu Ser Arg Leu Phe Trp Ser
    45                  50                  55

CAA CTT GAG CAC ATA AAC TGG GAT GGA GCC ACA GCC AAG AAC TTT ATT      303
Gln Leu Glu His Ile Asn Trp Asp Gly Ala Thr Ala Lys Asn Phe Ile
60                  65                  70                  75

AAT TTA AGG GAG TTC TTC TCT TTT CTG CTC CCT GCA TTG AGA AAA GCT      351
Asn Leu Arg Glu Phe Phe Ser Phe Leu Leu Pro Ala Leu Arg Lys Ala
                80                  85                  90

CAA ATT GAA ATT ATT CCA TGC AAG ATC TGT GGA GAC AAA TCA TCA GGA      399
Gln Ile Glu Ile Ile Pro Cys Lys Ile Cys Gly Asp Lys Ser Ser Gly
            95                  100                 105

ATC CAT TAT GGT GTC ATT ACA TGT GAA GGC TGC AAG GGC TTT TTC AGG      447
Ile His Tyr Gly Val Ile Thr Cys Glu Gly Cys Lys Gly Phe Phe Arg
        110                 115                 120

AGA AGT CAG CAA AGC AAT GCC ACC TAC TCC TGT CCT CGT CAG AAG AAC      495
Arg Ser Gln Gln Ser Asn Ala Thr Tyr Ser Cys Pro Arg Gln Lys Asn
    125                 130                 135

TGT TTG ATT GAT CGA ACC AGT AGA AAC CGC TGC CAA CAC TGT CGA TTA      543
Cys Leu Ile Asp Arg Thr Ser Arg Asn Arg Cys Gln His Cys Arg Leu
140                 145                 150                 155

CAG AAA TGC CTT GCC GTA GGG ATG TCT CGA GAT GCT GTA AAA TTT GGC      591
Gln Lys Cys Leu Ala Val Gly Met Ser Arg Asp Ala Val Lys Phe Gly
                160                 165                 170

CGA ATG TCA AAA AAG CAG AGA GAC AGC TTG TAT GCA GAA GTA CAG AAA      639
Arg Met Ser Lys Lys Gln Arg Asp Ser Leu Tyr Ala Glu Val Gln Lys
            175                 180                 185
```

```
CAC CGG ATG CAG CAG CAG CAG CGC GAC CAC CAG CAG CAG CCT GGA GAG          687
His Arg Met Gln Gln Gln Gln Arg Asp His Gln Gln Gln Pro Gly Glu
        190                 195                 200

GCT GAG CCG CTG ACG CCC ACC TAC AAC ATC TCG GCC AAC GGG CTG ACG          735
Ala Glu Pro Leu Thr Pro Thr Tyr Asn Ile Ser Ala Asn Gly Leu Thr
    205                 210                 215

GAA CTT CAC GAC GAC CTC AGT AAC TAC ATT GAC GGG CAC ACC CCT GAG          783
Glu Leu His Asp Asp Leu Ser Asn Tyr Ile Asp Gly His Thr Pro Glu
220                 225                 230                 235

GGG AGT AAG GCA GAC TCC GCC GTC AGC AGC TTC TAC CTG GAC ATA CAG          831
Gly Ser Lys Ala Asp Ser Ala Val Ser Ser Phe Tyr Leu Asp Ile Gln
                240                 245                 250

CCT TCC CCA GAC CAG TCA GGT CTT GAT ATC AAT GGA ATC AAA CCA GAA          879
Pro Ser Pro Asp Gln Ser Gly Leu Asp Ile Asn Gly Ile Lys Pro Glu
            255                 260                 265

CCA ATA TGT GAC TAC ACA CCA GCA TCA GGC TTC TTT CCC TAC TGT TCG          927
Pro Ile Cys Asp Tyr Thr Pro Ala Ser Gly Phe Phe Pro Tyr Cys Ser
        270                 275                 280

TTC ACC AAC GGC GAG ACT TCC CCA ACT GTG TCC ATG GCA GAA TTA GAA          975
Phe Thr Asn Gly Glu Thr Ser Pro Thr Val Ser Met Ala Glu Leu Glu
    285                 290                 295

CAC CTT GCA CAG AAT ATA TCT AAA TCG CAT CTG GAA ACC TGC CAA TAC         1023
His Leu Ala Gln Asn Ile Ser Lys Ser His Leu Glu Thr Cys Gln Tyr
300                 305                 310                 315

TTG AGA GAA GAG CTC CAG CAG ATA ACG TGG CAG ACC TTT TTA CAG GAA         1071
Leu Arg Glu Glu Leu Gln Gln Ile Thr Trp Gln Thr Phe Leu Gln Glu
                320                 325                 330

GAA ATT GAG AAC TAT CAA AAC AAG CAG CGG GAG GTG ATG TGG CAA TTG         1119
Glu Ile Glu Asn Tyr Gln Asn Lys Gln Arg Glu Val Met Trp Gln Leu
            335                 340                 345

TGT GCC ATC AAA ATT ACA GAA GCT ATA CAG TAT GTG GTG GAG TTT GCC         1167
Cys Ala Ile Lys Ile Thr Glu Ala Ile Gln Tyr Val Val Glu Phe Ala
        350                 355                 360

AAA CGC ATT GAT GGA TTT ATG GAA CTG TGT CAA AAT GAT CAA ATT GTG         1215
Lys Arg Ile Asp Gly Phe Met Glu Leu Cys Gln Asn Asp Gln Ile Val
    365                 370                 375

CTT CTA AAA GCA GGT TCT CTA GAG GTG GTG TTT ATC AGA ATG TGC CGT         1263
Leu Leu Lys Ala Gly Ser Leu Glu Val Val Phe Ile Arg Met Cys Arg
380                 385                 390                 395

GCC TTT GAC TCT CAG AAC AAC ACC GTG TAC TTT GAT GGG AAG TAT GCC         1311
Ala Phe Asp Ser Gln Asn Asn Thr Val Tyr Phe Asp Gly Lys Tyr Ala
                400                 405                 410

AGC CCC GAC GTC TTC AAA TCC TTA GGT TGT GAA GAC TTT ATT AGC TTT         1359
Ser Pro Asp Val Phe Lys Ser Leu Gly Cys Glu Asp Phe Ile Ser Phe
            415                 420                 425

GTG TTT GAA TTT GGA AAG AGT TTA TGT TCT ATG CAC CTG ACT GAA GAT         1407
Val Phe Glu Phe Gly Lys Ser Leu Cys Ser Met His Leu Thr Glu Asp
        430                 435                 440

GAA ATT GCA TTA TTT TCT GCA TTT GTA CTG ATG TCA GCA GAT CGC TCA         1455
Glu Ile Ala Leu Phe Ser Ala Phe Val Leu Met Ser Ala Asp Arg Ser
    445                 450                 455
```

```
TGG CTG CAA GAA AAG GTA AAA ATT GAA AAA CTG CAA CAG AAA ATT CAG      1503
Trp Leu Gln Glu Lys Val Lys Ile Glu Lys Leu Gln Gln Lys Ile Gln
460                 465                 470                 475

CTA GCT CTT CAA CAC GTC CTA CAG AAG AAT CAC CGA GAA GAT GGA ATA      1551
Leu Ala Leu Gln His Val Leu Gln Lys Asn His Arg Glu Asp Gly Ile
                480                 485                 490

CTA ACA AAG TTA ATA TGC AAG GTG TCT ACA TTA AGA GCC TTA TGT GGA      1599
Leu Thr Lys Leu Ile Cys Lys Val Ser Thr Leu Arg Ala Leu Cys Gly
            495                 500                 505

CGA CAT ACA GAA AAG CTA ATG GCA TTT AAA GCA ATA TAC CCA GAC ATT      1647
Arg His Thr Glu Lys Leu Met Ala Phe Lys Ala Ile Tyr Pro Asp Ile
        510                 515                 520

GTG CGA CTT CAT TTT CCT CCA TTA TAC AAG GAG TTG TTC ACT TCA GAA      1695
Val Arg Leu His Phe Pro Pro Leu Tyr Lys Glu Leu Phe Thr Ser Glu
    525                 530                 535

TTT GAG CCA GCA ATG CAA ATT GAT GGG TAAATGTTAT CACCTAAGCA            1742
Phe Glu Pro Ala Met Gln Ile Asp Gly
540                 545

CTTCTAGAAT GTCTGAAGTA CAAACATGAA AAACAAACAA AAAAATTAAC CGAGACACTT    1802

TATATGGCCC TGCACAGACC TGGAGCGCCA CACACTGCAC ATCTTTTGGT GATCGGGGTC    1862

AGGCAAAGGA GGGGAAACAA TGAAAACAAA TAAAGTTGAA CTTGTTTTTC TCAAAAAAAA    1922

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA                                     1952
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 548 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Asn Glu Gly Ala Pro Gly Asp Ser Asp Leu Glu Thr Glu Ala Arg
 1               5                  10                  15

Val Pro Trp Ser Ile Met Gly His Cys Leu Arg Thr Gly Gln Ala Arg
            20                  25                  30

Met Ser Ala Thr Pro Thr Pro Ala Gly Glu Gly Ala Arg Ser Ser Ser
        35                  40                  45

Thr Cys Ser Ser Leu Ser Arg Leu Phe Trp Ser Gln Leu Glu His Ile
    50                  55                  60

Asn Trp Asp Gly Ala Thr Ala Lys Asn Phe Ile Asn Leu Arg Glu Phe
65                  70                  75                  80

Phe Ser Phe Leu Leu Pro Ala Leu Arg Lys Ala Gln Ile Glu Ile Ile
                85                  90                  95

Pro Cys Lys Ile Cys Gly Asp Lys Ser Ser Gly Ile His Tyr Gly Val
            100                 105                 110

Ile Thr Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Gln Gln Ser
        115                 120                 125
```

```
Asn Ala Thr Tyr Ser Cys Pro Arg Gln Lys Asn Cys Leu Ile Asp Arg
    130                 135                 140

Thr Ser Arg Asn Arg Cys Gln His Cys Arg Leu Gln Lys Cys Leu Ala
145                 150                 155                 160

Val Gly Met Ser Arg Asp Ala Val Lys Phe Gly Arg Met Ser Lys Lys
                165                 170                 175

Gln Arg Asp Ser Leu Tyr Ala Glu Val Gln Lys His Arg Met Gln Gln
            180                 185                 190

Gln Gln Arg Asp His Gln Gln Gln Pro Gly Glu Ala Glu Pro Leu Thr
        195                 200                 205

Pro Thr Tyr Asn Ile Ser Ala Asn Gly Leu Thr Glu Leu His Asp Asp
    210                 215                 220

Leu Ser Asn Tyr Ile Asp Gly His Thr Pro Glu Gly Ser Lys Ala Asp
225                 230                 235                 240

Ser Ala Val Ser Ser Phe Tyr Leu Asp Ile Gln Pro Ser Pro Asp Gln
                245                 250                 255

Ser Gly Leu Asp Ile Asn Gly Ile Lys Pro Glu Pro Ile Cys Asp Tyr
            260                 265                 270

Thr Pro Ala Ser Gly Phe Phe Pro Tyr Cys Ser Phe Thr Asn Gly Glu
        275                 280                 285

Thr Ser Pro Thr Val Ser Met Ala Glu Leu Glu His Leu Ala Gln Asn
    290                 295                 300

Ile Ser Lys Ser His Leu Glu Thr Cys Gln Tyr Leu Arg Glu Glu Leu
305                 310                 315                 320

Gln Gln Ile Thr Trp Gln Thr Phe Leu Gln Glu Glu Ile Glu Asn Tyr
                325                 330                 335

Gln Asn Lys Gln Arg Glu Val Met Trp Gln Leu Cys Ala Ile Lys Ile
            340                 345                 350

Thr Glu Ala Ile Gln Tyr Val Val Glu Phe Ala Lys Arg Ile Asp Gly
        355                 360                 365

Phe Met Glu Leu Cys Gln Asn Asp Gln Ile Val Leu Leu Lys Ala Gly
    370                 375                 380

Ser Leu Glu Val Val Phe Ile Arg Met Cys Arg Ala Phe Asp Ser Gln
385                 390                 395                 400

Asn Asn Thr Val Tyr Phe Asp Gly Lys Tyr Ala Ser Pro Asp Val Phe
                405                 410                 415

Lys Ser Leu Gly Cys Glu Asp Phe Ile Ser Phe Val Phe Glu Phe Gly
            420                 425                 430

Lys Ser Leu Cys Ser Met His Leu Thr Glu Asp Glu Ile Ala Leu Phe
        435                 440                 445

Ser Ala Phe Val Leu Met Ser Ala Asp Arg Ser Trp Leu Gln Glu Lys
    450                 455                 460

Val Lys Ile Glu Lys Leu Gln Gln Lys Ile Gln Leu Ala Leu Gln His
465                 470                 475                 480
```

```
Val Leu Gln Lys Asn His Arg Glu Asp Gly Ile Leu Thr Lys Leu Ile
485                 490                 495

Cys Lys Val Ser Thr Leu Arg Ala Leu Cys Gly Arg His Thr Glu Lys
500                 505                 510

Leu Met Ala Phe Lys Ala Ile Tyr Pro Asp Ile Val Arg Leu His Phe
515                 520                 525

Pro Pro Leu Tyr Lys Glu Leu Phe Thr Ser Glu Phe Glu Pro Ala Met
530                 535                 540

Gln Ile Asp Gly
545
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 386 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: AMINO TERMINAL PORTION OF XR1PRIME (VERHT3.SEQ)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 90..386

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
CCATCTGTCT GATCACCTTG GACTCCATAG TACACTGGGG CAAAGCACAG CCCCAGTTTC      60

TGGAGGCAGA TGGGTAACCA GGAAAAGGC ATG AAT GAG GGG GCC CCA GGA GAC      113
                                Met Asn Glu Gly Ala Pro Gly Asp
                                  1               5

AGT GAC TTA GAG ACT GAG GCA AGA GTG CCG TGG TCA ATC ATG GGT CAT      161
Ser Asp Leu Glu Thr Glu Ala Arg Val Pro Trp Ser Ile Met Gly His
 10                  15                  20

TGT CTT CGA ACT GGA CAG GCC AGA ATG TCT GCC ACA CCC ACA CCT GCA      209
Cys Leu Arg Thr Gly Gln Ala Arg Met Ser Ala Thr Pro Thr Pro Ala
 25                  30                  35                  40

GGT GAA GGA GCC AGA AGG GAT GAA CTT TTT GGG ATT CTC CAA ATA CTC      257
Gly Glu Gly Ala Arg Arg Asp Glu Leu Phe Gly Ile Leu Gln Ile Leu
                 45                  50                  55

CAT CAG TGT ATC CTG TCT TCA GGT GAT GCT TTT GTT CTT ACT GGC GTC      305
His Gln Cys Ile Leu Ser Ser Gly Asp Ala Phe Val Leu Thr Gly Val
             60                  65                  70

TGT TGT TCC TGG AGG CAG AAT GGC AAG CCA CCA TAT TCA CAA AAG GAA      353
Cys Cys Ser Trp Arg Gln Asn Gly Lys Pro Pro Tyr Ser Gln Lys Glu
         75                  80                  85

GAT AAG GAA GTA CAA ACT GGA TAC ATG AAT GCT                          386
Asp Lys Glu Val Gln Thr Gly Tyr Met Asn Ala
 90                  95
```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 99 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Met Asn Glu Gly Ala Pro Gly Asp Ser Asp Leu Glu Thr Glu Ala Arg
 1               5                  10                  15

Val Pro Trp Ser Ile Met Gly His Cys Leu Arg Thr Gly Gln Ala Arg
            20                  25                  30

Met Ser Ala Thr Pro Thr Pro Ala Gly Glu Gly Ala Arg Arg Asp Glu
        35                  40                  45

Leu Phe Gly Ile Leu Gln Ile Leu His Gln Cys Ile Leu Ser Ser Gly
    50                  55                  60

Asp Ala Phe Val Leu Thr Gly Val Cys Cys Ser Trp Arg Gln Asn Gly
65                  70                  75                  80

Lys Pro Pro Tyr Ser Gln Lys Glu Asp Lys Glu Val Gln Thr Gly Tyr
                85                  90                  95

Met Asn Ala
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 300 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: AMINO TERMINAL PORTION OF XR1PRIM2 (VERHR5.SEQ)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 103..300

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
GTTTTTTTTT TTTTTTTGGT ACCATAGAGT TGCTCTGAAA ACAGAAGATA GAGGGAGTCT      60

CGGAGCTCGC CATCTCCAGC GATCTCTACA TTGGGAAAAA AC ATG GAG TCA GCT         114
                                                Met Glu Ser Ala
                                                  1

CCG GCA AGG GAG ACC CCG CTG AAC CAG GAA TCC GCC GCC CCC GAC CCC       162
Pro Ala Arg Glu Thr Pro Leu Asn Gln Glu Ser Ala Ala Pro Asp Pro
  5                  10                  15                  20

GCC GCC AGC GAG CCA GGC AGC AGC GGC GCG GAC GCG GCC GCC GGC TCC       210
Ala Ala Ser Glu Pro Gly Ser Ser Gly Ala Asp Ala Ala Ala Gly Ser
                25                  30                  35
```

```
CGC AAG AGC GAG CCG CCT GCC CCG GTG CGC AGA CAG AGC TAT TCC AGC        258
Arg Lys Ser Glu Pro Pro Ala Pro Val Arg Arg Gln Ser Tyr Ser Ser
            40                  45                  50

ACC AGC AGA GGT ATC TCA GTA ACG AAG AAG ACA CAT ACA TCT              300
Thr Ser Arg Gly Ile Ser Val Thr Lys Lys Thr His Thr Ser
        55                  60                  65
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met Glu Ser Ala Pro Ala Arg Glu Thr Pro Leu Asn Gln Glu Ser Ala
 1               5                  10                  15

Ala Pro Asp Pro Ala Ala Ser Glu Pro Gly Ser Ser Gly Ala Asp Ala
            20                  25                  30

Ala Ala Gly Ser Arg Lys Ser Glu Pro Pro Ala Pro Val Arg Arg Gln
        35                  40                  45

Ser Tyr Ser Ser Thr Ser Arg Gly Ile Ser Val Thr Lys Lys Thr His
    50                  55                  60

Thr Ser
65
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1659 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: XR2 (XR2.SEG)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 148..1470

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
GATATCCGTG ACATCATTGC CTGAGTCCAC TGCAAAAAGC TGTCCCCAGA GCAGGAGGGC     60

AATGACAGCT CCCAGGGCAC TCATCTTGAC TGCTCTTGCC TGGGGATTTG GACAGTGCCT    120

TGGTAATGAC CAGGGCTCCA GAAAGAG ATG TCC TTG TGG CTG GGG GCC CCT        171
                              Met Ser Leu Trp Leu Gly Ala Pro
                                1               5

GTG CCT GAC ATT CCT CCT GAC TCT GCG GTG GAG CTG TGG AAG CCA GGC      219
Val Pro Asp Ile Pro Pro Asp Ser Ala Val Glu Leu Trp Lys Pro Gly
    10                  15                  20
```

```
GCA CAG GAT GCA AGC AGC CAG GCC CAG GGA GGC AGC AGC TGC ATC CTC        267
Ala Gln Asp Ala Ser Ser Gln Ala Gln Gly Gly Ser Ser Cys Ile Leu
 25                  30                  35                  40

AGA GAG GAA GCC AGG ATG CCC CAC TCT GCT GGG GGT ACT GCA GAG CCC        315
Arg Glu Glu Ala Arg Met Pro His Ser Ala Gly Gly Thr Ala Glu Pro
                 45                  50                  55

ACA GCC CTG CTC ACC AGG GCA GAG CCC CCT TCA GAA CCC ACA GAG ATC        363
Thr Ala Leu Leu Thr Arg Ala Glu Pro Pro Ser Glu Pro Thr Glu Ile
             60                  65                  70

CGT CCA CAA AAG CGG AAA AAG GGG CCA GCC CCC AAA ATG CTG GGG AAC        411
Arg Pro Gln Lys Arg Lys Lys Gly Pro Ala Pro Lys Met Leu Gly Asn
         75                  80                  85

GAG CTA TGC AGC GTG TGT GGG GAC AAG GCC TCG GGC TTC CAC TAC AAT        459
Glu Leu Cys Ser Val Cys Gly Asp Lys Ala Ser Gly Phe His Tyr Asn
     90                  95                 100

GTT CTG AGC TGC GAG GGC TGC AAG GGA TTC TTC CGC CGC AGC GTC ATC        507
Val Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Val Ile
105                 110                 115                 120

AAG GGA GCG CAC TAC ATC TGC CAC AGT GGC GGC CAC TGC CCC ATG GAC        555
Lys Gly Ala His Tyr Ile Cys His Ser Gly Gly His Cys Pro Met Asp
                125                 130                 135

ACC TAC ATG CGT CGC AAG TGC CAG GAG TGT CGG CTT CGC AAA TGC CGT        603
Thr Tyr Met Arg Arg Lys Cys Gln Glu Cys Arg Leu Arg Lys Cys Arg
            140                 145                 150

CAG GCT GGC ATG CGG GAG GAG TGT GTC CTG TCA GAA GAA CAG ATC CGC        651
Gln Ala Gly Met Arg Glu Glu Cys Val Leu Ser Glu Glu Gln Ile Arg
        155                 160                 165

CTG AAG AAA CTG AAG CGG CAA GAG GAG GAA CAG GCT CAT GCC ACA TCC        699
Leu Lys Lys Leu Lys Arg Gln Glu Glu Glu Gln Ala His Ala Thr Ser
    170                 175                 180

TTG CCC CCC AGG CGT TCC TCA CCC CCC CAA ATC CTG CCC CAG CTC AGC        747
Leu Pro Pro Arg Arg Ser Ser Pro Pro Gln Ile Leu Pro Gln Leu Ser
185                 190                 195                 200

CCG GAA CAA CTG GGC ATG ATC GAG AAG CTC GTC GCT GCC CAG CAA CAG        795
Pro Glu Gln Leu Gly Met Ile Glu Lys Leu Val Ala Ala Gln Gln Gln
                205                 210                 215

TGT AAC CGG CGC TCC TTT TCT GAC CGG CTT CGA GTC ACG CCT TGG CCC        843
Cys Asn Arg Arg Ser Phe Ser Asp Arg Leu Arg Val Thr Pro Trp Pro
            220                 225                 230

ATG GCA CCA GAT CCC CAT AGC CGG GAG GCC CGT CAG CAG CGC TTT GCC        891
Met Ala Pro Asp Pro His Ser Arg Glu Ala Arg Gln Gln Arg Phe Ala
        235                 240                 245

CAC TTC ACT GAG CTG GCC ATC GTC TCT GTG CAG GAG ATA GTT GAC TTT        939
His Phe Thr Glu Leu Ala Ile Val Ser Val Gln Glu Ile Val Asp Phe
    250                 255                 260

GCT AAA CAG CTA CCC GGC TTC CTG CAG CTC AGC CGG GAG GAC CAG ATT        987
Ala Lys Gln Leu Pro Gly Phe Leu Gln Leu Ser Arg Glu Asp Gln Ile
265                 270                 275                 280

GCC CTG CTG AAG ACC TCT GCG ATC GAG GTG ATG CTT CTG GAG ACA TCT       1035
Ala Leu Leu Lys Thr Ser Ala Ile Glu Val Met Leu Leu Glu Thr Ser
                285                 290                 295
```

```
CGG AGG TAC AAC CCT GGG AGT GAG AGT ATC ACC TTC CTC AAG GAT TTC      1083
Arg Arg Tyr Asn Pro Gly Ser Glu Ser Ile Thr Phe Leu Lys Asp Phe
            300                 305                 310

AGT TAT AAC CGG GAA GAC TTT GCC AAA GCA GGG CTG CAA GTG GAA TTC      1131
Ser Tyr Asn Arg Glu Asp Phe Ala Lys Ala Gly Leu Gln Val Glu Phe
        315                 320                 325

ATC AAC CCC ATC TTC GAG TTC TCC AGG GCC ATG AAT GAG CTG CAA CTC      1179
Ile Asn Pro Ile Phe Glu Phe Ser Arg Ala Met Asn Glu Leu Gln Leu
    330                 335                 340

AAT GAT GCC GAG TTT GCC TTG CTC ATT GCT ATC AGC ATC TTC TCT GCA      1227
Asn Asp Ala Glu Phe Ala Leu Leu Ile Ala Ile Ser Ile Phe Ser Ala
345                 350                 355                 360

GAC CGG CCC AAC GTG CAG GAC CAG CTC CAG GTG GAG AGG CTG CAG CAC      1275
Asp Arg Pro Asn Val Gln Asp Gln Leu Gln Val Glu Arg Leu Gln His
                365                 370                 375

ACA TAT GTG GAA GCC CTG CAT GCC TAC GTC TCC ATC CAC CAT CCC CAT      1323
Thr Tyr Val Glu Ala Leu His Ala Tyr Val Ser Ile His His Pro His
            380                 385                 390

GAC CGA CTG ATG TTC CCA CGG ATG CTA ATG AAA CTG GTG AGC CTC CGG      1371
Asp Arg Leu Met Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg
        395                 400                 405

ACC CTG AGC AGC GTC CAC TCA GAG CAA GTG TTT GCA CTG CGT CTG CAG      1419
Thr Leu Ser Ser Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln
    410                 415                 420

GAC AAA AAG CTC CCA CCG CTG CTC TCT GAG ATC TGG GAT GTG CAC GAA      1467
Asp Lys Lys Leu Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu
425                 430                 435                 440

TGACTGTTCT GTCCCCATAT TTTCTGTTTT CTTGGCCGGA TGGCTGAGGC CTGGTGGCTG    1527

CCTCCTAGAA GTGGAACAGA CTGAGAAGGG CAAACATTCC TGGGAGCTGG GCAAGGAGAT    1587

CCTCCCGTGG CATTAAAAGA GAGTCAAAGG GTAAAAAAAA AAAAAAAAAA AAAAAAAAAA    1647

AAAAAGGAAT TC                                                       1659
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 440 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
Met Ser Leu Trp Leu Gly Ala Pro Val Pro Asp Ile Pro Pro Asp Ser
 1               5                  10                  15

Ala Val Glu Leu Trp Lys Pro Gly Ala Gln Asp Ala Ser Ser Gln Ala
            20                  25                  30

Gln Gly Gly Ser Ser Cys Ile Leu Arg Glu Glu Ala Arg Met Pro His
        35                  40                  45

Ser Ala Gly Gly Thr Ala Glu Pro Thr Ala Leu Leu Thr Arg Ala Glu
    50                  55                  60
```

```
Pro Pro Ser Glu Pro Thr Glu Ile Arg Pro Gln Lys Arg Lys Lys Gly
 65                  70                  75                  80

Pro Ala Pro Lys Met Leu Gly Asn Glu Leu Cys Ser Val Cys Gly Asp
                85                  90                  95

Lys Ala Ser Gly Phe His Tyr Asn Val Leu Ser Cys Glu Gly Cys Lys
            100                 105                 110

Gly Phe Phe Arg Arg Ser Val Ile Lys Gly Ala His Tyr Ile Cys His
        115                 120                 125

Ser Gly Gly His Cys Pro Met Asp Thr Tyr Met Arg Arg Lys Cys Gln
    130                 135                 140

Glu Cys Arg Leu Arg Lys Cys Arg Gln Ala Gly Met Arg Glu Glu Cys
145                 150                 155                 160

Val Leu Ser Glu Glu Gln Ile Arg Leu Lys Lys Leu Lys Arg Gln Glu
                165                 170                 175

Glu Glu Gln Ala His Ala Thr Ser Leu Pro Pro Arg Arg Ser Ser Pro
            180                 185                 190

Pro Gln Ile Leu Pro Gln Leu Ser Pro Glu Gln Leu Gly Met Ile Glu
        195                 200                 205

Lys Leu Val Ala Ala Gln Gln Gln Cys Asn Arg Arg Ser Phe Ser Asp
    210                 215                 220

Arg Leu Arg Val Thr Pro Trp Pro Met Ala Pro Asp Pro His Ser Arg
225                 230                 235                 240

Glu Ala Arg Gln Gln Arg Phe Ala His Phe Thr Glu Leu Ala Ile Val
                245                 250                 255

Ser Val Gln Glu Ile Val Asp Phe Ala Lys Gln Leu Pro Gly Phe Leu
            260                 265                 270

Gln Leu Ser Arg Glu Asp Gln Ile Ala Leu Leu Lys Thr Ser Ala Ile
        275                 280                 285

Glu Val Met Leu Leu Glu Thr Ser Arg Arg Tyr Asn Pro Gly Ser Glu
    290                 295                 300

Ser Ile Thr Phe Leu Lys Asp Phe Ser Tyr Asn Arg Glu Asp Phe Ala
305                 310                 315                 320

Lys Ala Gly Leu Gln Val Glu Phe Ile Asn Pro Ile Phe Glu Phe Ser
                325                 330                 335

Arg Ala Met Asn Glu Leu Gln Leu Asn Asp Ala Glu Phe Ala Leu Leu
            340                 345                 350

Ile Ala Ile Ser Ile Phe Ser Ala Asp Arg Pro Asn Val Gln Asp Gln
        355                 360                 365

Leu Gln Val Glu Arg Leu Gln His Thr Tyr Val Glu Ala Leu His Ala
    370                 375                 380

Tyr Val Ser Ile His His Pro His Asp Arg Leu Met Phe Pro Arg Met
385                 390                 395                 400

Leu Met Lys Leu Val Ser Leu Arg Thr Leu Ser Ser Val His Ser Glu
                405                 410                 415
```

```
Gln Val Phe Ala Leu Arg Leu Gln Asp Lys Lys Leu Pro Pro Leu Leu
            420                 425                 430

Ser Glu Ile Trp Asp Val His Glu
        435                 440
```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2009 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: XR4 (XR4.SEG)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 263..1582

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```
GAATTCCCTG GGGATTAATG GGAAAAGTTT TGGCAGGAGC TGGGGGATTC TGCGGAGCCT      60

GCGGGACGGC GGCAGCGGCG CGAGAGGCGG CCGGGACAGT GCTGTGCAGC GGTGTGGGTA     120

TGCGCATGGG ACTCACTCAG AGGCTCCTGC TCACTGACAG ATGAAGACAA ACCCACGGTA     180

AAGGCAGTCC ATCTGCGCTC AGACCCAGAT GGTGGCAGAG CTATGACCAG GCCTGCAGCG     240

CCACGCCAAG TGGGGGTCAG TC ATG GAA CAG CCA CAG GAG GAG ACC CCT GAG      292
                         Met Glu Gln Pro Gln Glu Glu Thr Pro Glu
                           1               5                  10

GCC CGG GAA GAG GAG AAA GAG GAA GTG GCC ATG GGT GAC GGA GCC CCG      340
Ala Arg Glu Glu Glu Lys Glu Glu Val Ala Met Gly Asp Gly Ala Pro
                  15                  20                  25

GAG CTC AAT GGG GGA CCA GAA CAC ACG CTT CCT TCC AGC AGC TGT GCA      388
Glu Leu Asn Gly Gly Pro Glu His Thr Leu Pro Ser Ser Ser Cys Ala
              30                  35                  40

GAC CTC TCC CAG AAT TCC TCC CCT TCC TCC CTG CTG GAC CAG CTG CAG      436
Asp Leu Ser Gln Asn Ser Ser Pro Ser Ser Leu Leu Asp Gln Leu Gln
          45                  50                  55

ATG GGC TGT GAT GGG GCC TCA GGC GGC AGC CTC AAC ATG GAA TGT CGG      484
Met Gly Cys Asp Gly Ala Ser Gly Gly Ser Leu Asn Met Glu Cys Arg
      60                  65                  70

GTG TGC GGG GAC AAG GCC TCG GGC TTC CAC TAC GGG GTC CAC GCG TGC      532
Val Cys Gly Asp Lys Ala Ser Gly Phe His Tyr Gly Val His Ala Cys
  75                  80                  85                  90

GAG GGG TGC AAG GGC TTC TTC CGC CGG ACA ATC CGC ATG AAG CTC GAG      580
Glu Gly Cys Lys Gly Phe Phe Arg Arg Thr Ile Arg Met Lys Leu Glu
                  95                 100                 105
```

```
TAT GAG AAG TGC GAT CGG ATC TGC AAG ATC CAG AAG AAG AAC CGC AAC          628
Tyr Glu Lys Cys Asp Arg Ile Cys Lys Ile Gln Lys Lys Asn Arg Asn
                110                 115                 120

AAG TGT CAG TAC TGC CGC TTC CAG AAG TGC CTG GCA CTC GGC ATG TCG          676
Lys Cys Gln Tyr Cys Arg Phe Gln Lys Cys Leu Ala Leu Gly Met Ser
        125                 130                 135

CAC AAC GCT ATC CGC TTT GGA CGG ATG CCG GAC GGC GAG AAG AGG AAG          724
His Asn Ala Ile Arg Phe Gly Arg Met Pro Asp Gly Glu Lys Arg Lys
    140                 145                 150

CTG GTG GCG GGG CTG ACT GCC AGC GAG GGG TGC CAG CAC AAC CCC CAG          772
Leu Val Ala Gly Leu Thr Ala Ser Glu Gly Cys Gln His Asn Pro Gln
155                 160                 165                 170

CTG GCC GAC CTG AAG GCC TTC TCT AAG CAC ATC TAC AAC GCC TAC CTG          820
Leu Ala Asp Leu Lys Ala Phe Ser Lys His Ile Tyr Asn Ala Tyr Leu
                175                 180                 185

AAA AAC TTC AAC ATG ACC AAA AAG AAG GCC CGG AGC ATC CTC ACC GGC          868
Lys Asn Phe Asn Met Thr Lys Lys Lys Ala Arg Ser Ile Leu Thr Gly
            190                 195                 200

AAG TCC AGC CAC AAC GCA CCC TTT GTC ATC CAC GAC ATC GAG ACA CTG          916
Lys Ser Ser His Asn Ala Pro Phe Val Ile His Asp Ile Glu Thr Leu
        205                 210                 215

TGG CAG GCA GAG AAG GGC CTG GTG TGG AAA CAG CTG GTG AAC GTG CCG          964
Trp Gln Ala Glu Lys Gly Leu Val Trp Lys Gln Leu Val Asn Val Pro
    220                 225                 230

CCC TAC AAC GAG ATC AGT GTG CAC GTG TTC TAC CGC TGC CAG TCC ACC         1012
Pro Tyr Asn Glu Ile Ser Val His Val Phe Tyr Arg Cys Gln Ser Thr
235                 240                 245                 250

ACA GTG GAG ACA GTC CGA GAG CTC ACC GAG TTC GCC AAG AAC ATC CCC         1060
Thr Val Glu Thr Val Arg Glu Leu Thr Glu Phe Ala Lys Asn Ile Pro
                255                 260                 265

AAC TTC AGC AGC CTC TTC CTC AAT GAC CAG GTG ACC CTC CTC AAG TAT         1108
Asn Phe Ser Ser Leu Phe Leu Asn Asp Gln Val Thr Leu Leu Lys Tyr
            270                 275                 280

GGC GTG CAC GAG GCC ATC TTT GCC ATG CTG GCC TCC ATC GTC AAC AAA         1156
Gly Val His Glu Ala Ile Phe Ala Met Leu Ala Ser Ile Val Asn Lys
        285                 290                 295

GAC GGG CTG CTG GTG GCC AAC GGC AGT GGC TTC GTC ACC CAC GAG TTC         1204
Asp Gly Leu Leu Val Ala Asn Gly Ser Gly Phe Val Thr His Glu Phe
    300                 305                 310

TTG CGA AGT CTC CGC AAG CCC TTC AGT GAC ATC ATT GAG CCC AAG TTC         1252
Leu Arg Ser Leu Arg Lys Pro Phe Ser Asp Ile Ile Glu Pro Lys Phe
315                 320                 325                 330

GAG TTT GCT GTC AAG TTC AAT GCG CTG GAG CTC GAT GAC AGT GAC CTG         1300
Glu Phe Ala Val Lys Phe Asn Ala Leu Glu Leu Asp Asp Ser Asp Leu
                335                 340                 345

GCG CTC TTC ATC GCG GCC ATC ATT CTG TGT GGA GAC CGG CCA GGC CTC         1348
Ala Leu Phe Ile Ala Ala Ile Ile Leu Cys Gly Asp Arg Pro Gly Leu
            350                 355                 360

ATG AAT GTG CCC CAG GTA GAA GCC ATC CAG GAC ACC ATT CTG CGG GCT         1396
Met Asn Val Pro Gln Val Glu Ala Ile Gln Asp Thr Ile Leu Arg Ala
        365                 370                 375
```

```
CTA GAA TTC CAT CTG CAG GTC AAC CAC CCT GAC AGC CAG TAC CTC TTC      1444
Leu Glu Phe His Leu Gln Val Asn His Pro Asp Ser Gln Tyr Leu Phe
    380                 385                 390

CCC AAG CTG CTG CAG AAG ATG GCA GAC CTG CGG CAC GTG GTC ACT GAG      1492
Pro Lys Leu Leu Gln Lys Met Ala Asp Leu Arg His Val Val Thr Glu
395                 400                 405                 410

CAT GCC CAG ATG ATG CAG TGG CTA AAG AAG ACG GAG AGT GAG ACC TTG      1540
His Ala Gln Met Met Gln Trp Leu Lys Lys Thr Glu Ser Glu Thr Leu
                415                 420                 425

CTG CAC CCC CTG CTC CAG GAA ATC TAC AAG GAC ATG TAC TAAGGCCGCA       1589
Leu His Pro Leu Leu Gln Glu Ile Tyr Lys Asp Met Tyr
            430                 435                 440

GCCCAGGCCT CCCCTCAGGC TCTGCTGGGC CCAGCCACGG ACTGTTCAGA GGACCAGCCA    1649

CAGGCACTGG CAGTCAAGCA GCTAGAGCCT ACTCACAACA CTCCAGACAC GTGGCCCAGA    1709

CTCTTCCCCC AACACCCCCA CCCCCACCAA CCCCCCCATT CCCCCAACCC CCCTCCCCCA    1769

CCCCGCTCTC CCCATGGCCC GTTTCCTGTT TCTCCTCAGC ACCTCCTGTT CTTGCTGTCT    1829

CCCTAGCGCC CTTGCTCCCC CCCCTTTGCC TTCCTTCTCT AGCATCCCCC TCCTCCCAGT    1889

CCTCACATTT GTCTGATTCA CAGCAGACAG CCCGTTGGTA CGCTCACCAG CAGCCTAAAA    1949

GCAGTGGGCC TGTGCTGGCC CAGTCCTGCC TCTCCTCTCT ATCCCCTTCA AAGGGAATTC    2009
```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 439 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```
Met Glu Gln Pro Gln Glu Glu Thr Pro Glu Ala Arg Glu Glu Glu Lys
  1               5                  10                  15

Glu Glu Val Ala Met Gly Asp Gly Ala Pro Glu Leu Asn Gly Gly Pro
            20                  25                  30

Glu His Thr Leu Pro Ser Ser Ser Cys Ala Asp Leu Ser Gln Asn Ser
        35                  40                  45

Ser Pro Ser Ser Leu Leu Asp Gln Leu Gln Met Gly Cys Asp Gly Ala
    50                  55                  60

Ser Gly Gly Ser Leu Asn Met Glu Cys Arg Val Cys Gly Asp Lys Ala
65                  70                  75                  80

Ser Gly Phe His Tyr Gly Val His Ala Cys Glu Gly Cys Lys Gly Phe
                85                  90                  95

Phe Arg Arg Thr Ile Arg Met Lys Leu Glu Tyr Glu Lys Cys Asp Arg
            100                 105                 110

Ile Cys Lys Ile Gln Lys Lys Asn Arg Asn Lys Cys Gln Tyr Cys Arg
        115                 120                 125
```

Phe Gln Lys Cys Leu Ala Leu Gly Met Ser His Asn Ala Ile Arg Phe
130 135 140

Gly Arg Met Pro Asp Gly Glu Lys Arg Lys Leu Val Ala Gly Leu Thr
145 150 155 160

Ala Ser Glu Gly Cys Gln His Asn Pro Gln Leu Ala Asp Leu Lys Ala
165 170 175

Phe Ser Lys His Ile Tyr Asn Ala Tyr Leu Lys Asn Phe Asn Met Thr
180 185 190

Lys Lys Lys Ala Arg Ser Ile Leu Thr Gly Lys Ser Ser His Asn Ala
195 200 205

Pro Phe Val Ile His Asp Ile Glu Thr Leu Trp Gln Ala Glu Lys Gly
210 215 220

Leu Val Trp Lys Gln Leu Val Asn Val Pro Pro Tyr Asn Glu Ile Ser
225 230 235 240

Val His Val Phe Tyr Arg Cys Gln Ser Thr Thr Val Glu Thr Val Arg
245 250 255

Glu Leu Thr Glu Phe Ala Lys Asn Ile Pro Asn Phe Ser Ser Leu Phe
260 265 270

Leu Asn Asp Gln Val Thr Leu Leu Lys Tyr Gly Val His Glu Ala Ile
275 280 285

Phe Ala Met Leu Ala Ser Ile Val Asn Lys Asp Gly Leu Leu Val Ala
290 295 300

Asn Gly Ser Gly Phe Val Thr His Glu Phe Leu Arg Ser Leu Arg Lys
305 310 315 320

Pro Phe Ser Asp Ile Ile Glu Pro Lys Phe Glu Phe Ala Val Lys Phe
325 330 335

Asn Ala Leu Glu Leu Asp Asp Ser Asp Leu Ala Leu Phe Ile Ala Ala
340 345 350

Ile Ile Leu Cys Gly Asp Arg Pro Gly Leu Met Asn Val Pro Gln Val
355 360 365

Glu Ala Ile Gln Asp Thr Ile Leu Arg Ala Leu Glu Phe His Leu Gln
370 375 380

Val Asn His Pro Asp Ser Gln Tyr Leu Phe Pro Lys Leu Leu Gln Lys
385 390 395 400

Met Ala Asp Leu Arg His Val Val Thr Glu His Ala Gln Met Met Gln
405 410 415

Trp Leu Lys Lys Thr Glu Ser Glu Thr Leu Leu His Pro Leu Leu Gln
420 425 430

Glu Ile Tyr Lys Asp Met Tyr
435

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2468 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: XR5 (XR5.SEG)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1677

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```
GAA TTC CGG CGC GGA GGG GCG CGG CGC GAG GGG CCG GAG CCG GGC GGC        48
Glu Phe Arg Arg Gly Gly Ala Arg Arg Glu Gly Pro Glu Pro Gly Gly
 1               5                  10                  15

TCA GGG GCC CAG AGA GTG CGG CGG CCG AGA GCC TGC CGG CCC CTG ACA        96
Ser Gly Ala Gln Arg Val Arg Arg Pro Arg Ala Cys Arg Pro Leu Thr
            20                  25                  30

GCC CCC TCC CCC CGT GGA AGA CCA GGA CGA CGA CTA CGA AGG CGC AAG       144
Ala Pro Ser Pro Arg Gly Arg Pro Gly Arg Arg Leu Arg Arg Arg Lys
        35                  40                  45

TCA TGG CGG AGC AGC GAA CGC CGA GAG GGC CCT GAG CAC CGC CGC ATG       192
Ser Trp Arg Ser Ser Glu Arg Arg Glu Gly Pro Glu His Arg Arg Met
    50                  55                  60

GAG CGG GAC GAA CGG CCA CCT AGC GGA GGG GGA GGC GGC GGG GGC TCG       240
Glu Arg Asp Glu Arg Pro Pro Ser Gly Gly Gly Gly Gly Gly Gly Ser
65                  70                  75                  80

GCG GGG TTC CTG GAG CCG CCC GCC GCG CTC CCT CCG CCG CCG CGC AAC       288
Ala Gly Phe Leu Glu Pro Pro Ala Ala Leu Pro Pro Pro Pro Arg Asn
                85                  90                  95

GGT TTC TGT CAG GAT GAA TTG GCA GAG CTT GAT CCA GGC ACT AAT GGA       336
Gly Phe Cys Gln Asp Glu Leu Ala Glu Leu Asp Pro Gly Thr Asn Gly
            100                 105                 110

GAG ACT GAC AGT TTA ACA CTT GGC CAA GGC CAT ATA CCT GTT TCC GTC       384
Glu Thr Asp Ser Leu Thr Leu Gly Gln Gly His Ile Pro Val Ser Val
        115                 120                 125

CCA GAT GAT CGA GCT GAA CAA CGA ACC TGT CTC ATC TGT GGG GAC CGC       432
Pro Asp Asp Arg Ala Glu Gln Arg Thr Cys Leu Ile Cys Gly Asp Arg
    130                 135                 140

GCT ACG GGC TTG CAC TAT GGG ATC ATC TCC TGC GAG GGC TGC AAG GGG       480
Ala Thr Gly Leu His Tyr Gly Ile Ile Ser Cys Glu Gly Cys Lys Gly
145                 150                 155                 160

TTT TTC AAG AGG AGC ATT TGC AAC AAA CGG GTG TAT CGG TGC AGT CGT       528
Phe Phe Lys Arg Ser Ile Cys Asn Lys Arg Val Tyr Arg Cys Ser Arg
                165                 170                 175
```

```
GAC AAG AAC TGT GTC ATG TCC CGG AAG CAG AGG AAC AGA TGT CAG TAC          576
Asp Lys Asn Cys Val Met Ser Arg Lys Gln Arg Asn Arg Cys Gln Tyr
            180                 185                 190

TGC CGC CTG CTC AAG TGT CTC CAG ATG GGC ATG AAC AGG AAG GCT ATC          624
Cys Arg Leu Leu Lys Cys Leu Gln Met Gly Met Asn Arg Lys Ala Ile
        195                 200                 205

AGA GAA GAT GGC ATG CCT GGA GGC CGG AAC AAG AGC ATT GGA CCA GTC          672
Arg Glu Asp Gly Met Pro Gly Gly Arg Asn Lys Ser Ile Gly Pro Val
    210                 215                 220

CAG ATA TCA GAA GAA GAA ATT GAA AGA ATC ATG TCT GGA CAG GAG TTT          720
Gln Ile Ser Glu Glu Glu Ile Glu Arg Ile Met Ser Gly Gln Glu Phe
225                 230                 235                 240

GAG GAA GAA GCC AAT CAC TGG AGC AAC CAT GGT GAC AGC GAC CAC AGT          768
Glu Glu Glu Ala Asn His Trp Ser Asn His Gly Asp Ser Asp His Ser
                245                 250                 255

TCC CCT GGG AAC AGG GCT TCA GAG AGC AAC CAG CCC TCA CCA GGC TCC          816
Ser Pro Gly Asn Arg Ala Ser Glu Ser Asn Gln Pro Ser Pro Gly Ser
            260                 265                 270

ACA CTA TCA TCC AGT AGG TCT GTG GAA CTA AAT GGA TTC ATG GCA TTC          864
Thr Leu Ser Ser Ser Arg Ser Val Glu Leu Asn Gly Phe Met Ala Phe
        275                 280                 285

AGG GAT CAG TAC ATG GGG ATG TCA GTG CCT CCA CAT TAT CAA TAC ATA          912
Arg Asp Gln Tyr Met Gly Met Ser Val Pro Pro His Tyr Gln Tyr Ile
    290                 295                 300

CCA CAC CTT TTT AGC TAT TCT GGC CAC TCA CCA CTT TTG CCC CCA CAA          960
Pro His Leu Phe Ser Tyr Ser Gly His Ser Pro Leu Leu Pro Pro Gln
305                 310                 315                 320

GCT CGA AGC CTG GAC CCT CAG TCC TAC AGT CTG ATT CAT CAG CTG ATG         1008
Ala Arg Ser Leu Asp Pro Gln Ser Tyr Ser Leu Ile His Gln Leu Met
                325                 330                 335

TCA GCC GAA GAC CTG GAG CCA TTG GGC ACA CCT ATG TTG ATT GAA GAT         1056
Ser Ala Glu Asp Leu Glu Pro Leu Gly Thr Pro Met Leu Ile Glu Asp
            340                 345                 350

GGG TAT GCT GTG ACA CAG GCA GAA CTG TTT GCT CTG CTT TGC CGC CTG         1104
Gly Tyr Ala Val Thr Gln Ala Glu Leu Phe Ala Leu Leu Cys Arg Leu
        355                 360                 365

GCC GAC GAG TTG CTC TTT AGG CAG ATT GCC TGG ATC AAG AAG CTG CCT         1152
Ala Asp Glu Leu Leu Phe Arg Gln Ile Ala Trp Ile Lys Lys Leu Pro
    370                 375                 380

TTC TTC TGC GAG CTC TCA ATC AAG GAT TAC ACG TGC CTC TTG AGC TCT         1200
Phe Phe Cys Glu Leu Ser Ile Lys Asp Tyr Thr Cys Leu Leu Ser Ser
385                 390                 395                 400

ACG TGG CAG GAG TTA ATC CTG CTC TCC TCC CTC ACA GTG TAC AGC AAG         1248
Thr Trp Gln Glu Leu Ile Leu Leu Ser Ser Leu Thr Val Tyr Ser Lys
                405                 410                 415

CAG ATC TTT GGG GAG CTG GCT GAT GTC ACA GCC AAG TAC TCA CCC TCT         1296
Gln Ile Phe Gly Glu Leu Ala Asp Val Thr Ala Lys Tyr Ser Pro Ser
            420                 425                 430

GAT GAA GAA CTC CAC AGA TTT AGT GAT GAA GGG ATG GAG GTG ATT GAA         1344
Asp Glu Glu Leu His Arg Phe Ser Asp Glu Gly Met Glu Val Ile Glu
        435                 440                 445
```

```
CGA CTC ATC TAC CTA TAT CAC AAG TTC CAT CAG CTG AAG GTC AGC AAC      1392
Arg Leu Ile Tyr Leu Tyr His Lys Phe His Gln Leu Lys Val Ser Asn
    450                 455                 460

GAG GAG TAC GCA TGC ATG AAA GCA ATT AAC TTC CTG AAT CAA GAT ATC      1440
Glu Glu Tyr Ala Cys Met Lys Ala Ile Asn Phe Leu Asn Gln Asp Ile
465                 470                 475                 480

AGG GGT CTG ACC AGT GCC TCA CAG CTG GAA CAA CTG AAC AAG CGG TAT      1488
Arg Gly Leu Thr Ser Ala Ser Gln Leu Glu Gln Leu Asn Lys Arg Tyr
                485                 490                 495

TGG TAC ATT TGT CAG GAT TTC ACT GAA TAT AAA TAC ACA CAT CAG CCA      1536
Trp Tyr Ile Cys Gln Asp Phe Thr Glu Tyr Lys Tyr Thr His Gln Pro
            500                 505                 510

AAC CGC TTT CCT GAT CTT ATG ATG TGC TTG CCA GAG ATC CGA TAC ATC      1584
Asn Arg Phe Pro Asp Leu Met Met Cys Leu Pro Glu Ile Arg Tyr Ile
        515                 520                 525

GCA GGC AAG ATG GTG AAT GTG CCC CTG GAG CAG CTG CCC CTC CTC TTT      1632
Ala Gly Lys Met Val Asn Val Pro Leu Glu Gln Leu Pro Leu Leu Phe
    530                 535                 540

AAG GTG GTG CTG CAC TCC TGC AAG ACA AGT ACG GTG AAG GAG TGACCTGTGC   1684
Lys Val Val Leu His Ser Cys Lys Thr Ser Thr Val Lys Glu
545                 550                 555

CCTGCACCTC CTTGGGCCAC CCACAGTGCC TTGGGTAGGC AGCACAGGCT CCAGAGGAAA   1744

GAGCCAGAGA CCAAGATGGA GACTGTGGAG CAGCTACCTC CATCACAAGA AGAATTTGTT   1804

TGTTTGTCTG TTTTTAACCT CATTTTTCTA TATATTTATT TCACGACAGA GTTGAATGTA   1864

TGGCCTTCAA CATGATGCAC ATGCTTTTGT GTGAATGCAG CAGATGCATT TCCTTGCAGT   1924

TTACAGAATG TGAAGATGTT TAATGTTACC GTGTTGTCAT TGTTTAGAGA TAGGTTTTTT   1984

TGTATTTTGA TGGAGAGGGT AGGATGGACT AGATGAGTAT TTCCATAATG TTGACAAAGA   2044

CAACTACCTC AATGGAAACA GGTGTATGAC CATCCCTACC TTTTTCCACA TTTTCTCAGC   2104

AGATACACAC TTGTCTGTTA GAGAGCAAAC TGCCTTTTTT ATAGCCACAG ACTTCTAAGT   2164

AAAAGAAGCA AACAAAGGAG CGAAGTGGTA TAGGGAGATT TACTAATGGC CAGTTGGGAC   2224

ATCTGAGAGG CAATTTGATT TTGATCATCT CATCCCACAA GCCTGAAGGC AGAAACTCTG   2284

CCTTACCTTC TGCTGCACCC CTCCCCCCCC CCACACGCTG TTGTCTGTTG ATGCTGCTGT   2344

CAAGTTTTCA TCCAGGTAGA GTCCTAACAA TAAGCCAGTA TGTAGGACTT GCCTCCCAGC   2404

GCCCTTGTAG CTCATAGCTG CCTAGTTTGC TGTTCTAGAT CTACCAAGGC CTACTTCGGA   2464

ATTC                                                                2468
```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 558 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Glu Phe Arg Arg Gly Gly Ala Arg Arg Glu Gly Pro Glu Pro Gly Gly
1 5 10 15

Ser Gly Ala Gln Arg Val Arg Arg Pro Arg Ala Cys Arg Pro Leu Thr
20 25 30

Ala Pro Ser Pro Arg Gly Arg Pro Gly Arg Arg Leu Arg Arg Arg Lys
35 40 45

Ser Trp Arg Ser Ser Glu Arg Arg Glu Gly Pro Glu His Arg Arg Met
50 55 60

Glu Arg Asp Glu Arg Pro Pro Ser Gly Gly Gly Gly Gly Gly Gly Ser
65 70 75 80

Ala Gly Phe Leu Glu Pro Pro Ala Ala Leu Pro Pro Pro Pro Arg Asn
85 90 95

Gly Phe Cys Gln Asp Glu Leu Ala Glu Leu Asp Pro Gly Thr Asn Gly
100 105 110

Glu Thr Asp Ser Leu Thr Leu Gly Gln Gly His Ile Pro Val Ser Val
115 120 125

Pro Asp Asp Arg Ala Glu Gln Arg Thr Cys Leu Ile Cys Gly Asp Arg
130 135 140

Ala Thr Gly Leu His Tyr Gly Ile Ile Ser Cys Glu Gly Cys Lys Gly
145 150 155 160

Phe Phe Lys Arg Ser Ile Cys Asn Lys Arg Val Tyr Arg Cys Ser Arg
165 170 175

Asp Lys Asn Cys Val Met Ser Arg Lys Gln Arg Asn Arg Cys Gln Tyr
180 185 190

Cys Arg Leu Leu Lys Cys Leu Gln Met Gly Met Asn Arg Lys Ala Ile
195 200 205

Arg Glu Asp Gly Met Pro Gly Gly Arg Asn Lys Ser Ile Gly Pro Val
210 215 220

Gln Ile Ser Glu Glu Glu Ile Glu Arg Ile Met Ser Gly Gln Glu Phe
225 230 235 240

Glu Glu Glu Ala Asn His Trp Ser Asn His Gly Asp Ser Asp His Ser
245 250 255

Ser Pro Gly Asn Arg Ala Ser Glu Ser Asn Gln Pro Ser Pro Gly Ser
260 265 270

Thr Leu Ser Ser Ser Arg Ser Val Glu Leu Asn Gly Phe Met Ala Phe
275 280 285

Arg Asp Gln Tyr Met Gly Met Ser Val Pro Pro His Tyr Gln Tyr Ile
290 295 300

Pro His Leu Phe Ser Tyr Ser Gly His Ser Pro Leu Leu Pro Pro Gln
305 310 315 320

Ala Arg Ser Leu Asp Pro Gln Ser Tyr Ser Leu Ile His Gln Leu Met
325 330 335

Ser Ala Glu Asp Leu Glu Pro Leu Gly Thr Pro Met Leu Ile Glu Asp
340 345 350

Gly Tyr Ala Val Thr Gln Ala Glu Leu Phe Ala Leu Leu Cys Arg Leu
355 360 365

Ala Asp Glu Leu Leu Phe Arg Gln Ile Ala Trp Ile Lys Lys Leu Pro
370 375 380

Phe Phe Cys Glu Leu Ser Ile Lys Asp Tyr Thr Cys Leu Leu Ser Ser
385 390 395 400

Thr Trp Gln Glu Leu Ile Leu Leu Ser Ser Leu Thr Val Tyr Ser Lys
405 410 415

Gln Ile Phe Gly Glu Leu Ala Asp Val Thr Ala Lys Tyr Ser Pro Ser
420 425 430

Asp Glu Glu Leu His Arg Phe Ser Asp Glu Gly Met Glu Val Ile Glu
435 440 445

Arg Leu Ile Tyr Leu Tyr His Lys Phe His Gln Leu Lys Val Ser Asn
450 455 460

Glu Glu Tyr Ala Cys Met Lys Ala Ile Asn Phe Leu Asn Gln Asp Ile
465 470 475 480

Arg Gly Leu Thr Ser Ala Ser Gln Leu Glu Gln Leu Asn Lys Arg Tyr
485 490 495

Trp Tyr Ile Cys Gln Asp Phe Thr Glu Tyr Lys Tyr Thr His Gln Pro
500 505 510

Asn Arg Phe Pro Asp Leu Met Met Cys Leu Pro Glu Ile Arg Tyr Ile
515 520 525

Ala Gly Lys Met Val Asn Val Pro Leu Glu Gln Leu Pro Leu Leu Phe
530 535 540

Lys Val Val Leu His Ser Cys Lys Thr Ser Thr Val Lys Glu
545 550 555

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2315 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: XR79 (XR79.SEQ)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 204..2009

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```
GCGTTAGAAA AGGTTCAAAA TAGGCACAAA GTCGTGAAAA TATCGTAACT GACCGGAAGT      60

AACATAACTT TAACCAAGTG CCTCGAAAAA TAGATGTTTT TAAAAGCTCA AGAATGGTGA     120

TAACAGACGT CCAATAAGAA TTTTCAAAGA GCCAATTATT TATACAGCCG ACGACTATTT     180

TTTAGCCGCC TGCTGTGGCG ACA ATG GAC GGC GTT AAG GTT GAG ACG TTC          230
                          Met Asp Gly Val Lys Val Glu Thr Phe
                            1               5

ATC AAA AGC GAA GAA AAC CGA GCG ATG CCC TTG ATC GGA GGA GGC AGT       278
Ile Lys Ser Glu Glu Asn Arg Ala Met Pro Leu Ile Gly Gly Gly Ser
 10                  15                  20                  25

GCC TCA GGC GGC ACT CCT CTG CCA GGA GGC GGC GTG GGA ATG GGA GCC       326
Ala Ser Gly Gly Thr Pro Leu Pro Gly Gly Gly Val Gly Met Gly Ala
                 30                  35                  40

GGA GCA TCC GCA ACG TTG AGC GTG GAG CTG TGT TTG GTG TGC GGG GAC       374
Gly Ala Ser Ala Thr Leu Ser Val Glu Leu Cys Leu Val Cys Gly Asp
             45                  50                  55

CGC GCC TCC GGG CGG CAC TAC GGA GCC ATA AGC TGC GAA GGC TGC AAG       422
Arg Ala Ser Gly Arg His Tyr Gly Ala Ile Ser Cys Glu Gly Cys Lys
         60                  65                  70

GGA TTC TTC AAG CGC TCG ATC CGG AAG CAG CTG GGC TAC CAG TGT CGC       470
Gly Phe Phe Lys Arg Ser Ile Arg Lys Gln Leu Gly Tyr Gln Cys Arg
     75                  80                  85

GGG GCT ATG AAC TGC GAG GTC ACC AAG CAC CAC AGG AAT CGG TGC CAG       518
Gly Ala Met Asn Cys Glu Val Thr Lys His His Arg Asn Arg Cys Gln
 90                  95                 100                 105

TTC TGT CGA CTA CAG AAG TGC CTG GCC AGC GGC ATG CGA AGT GAT TCT       566
Phe Cys Arg Leu Gln Lys Cys Leu Ala Ser Gly Met Arg Ser Asp Ser
                110                 115                 120

GTG CAG CAC GAG AGG AAA CCG ATT GTG GAC AGG AAG GAG GGG ATC ATC       614
Val Gln His Glu Arg Lys Pro Ile Val Asp Arg Lys Glu Gly Ile Ile
            125                 130                 135

GCT GCT GCC GGT AGC TCA TCC ACT TCT GGC GGC GGT AAT GGC TCG TCC       662
Ala Ala Ala Gly Ser Ser Ser Thr Ser Gly Gly Gly Asn Gly Ser Ser
        140                 145                 150
```

```
ACC TAC CTA TCC GGC AAG TCC GGC TAT CAG CAG GGG CGT GGC AAG GGG          710
Thr Tyr Leu Ser Gly Lys Ser Gly Tyr Gln Gln Gly Arg Gly Lys Gly
    155                 160                 165

CAC AGT GTA AAG GCC GAA TCC GCG CCA CGC CTC CAG TGC ACA GCG CGC          758
His Ser Val Lys Ala Glu Ser Ala Pro Arg Leu Gln Cys Thr Ala Arg
170                 175                 180                 185

CAG CAA CGG GCC TTC AAT TTG AAT GCA GAA TAT ATT CCG ATG GGT TTG          806
Gln Gln Arg Ala Phe Asn Leu Asn Ala Glu Tyr Ile Pro Met Gly Leu
                190                 195                 200

AAT TTC GCA GAA CTA ACG CAG ACA TTG ATG TTC GCT ACC CAA CAG CAG          854
Asn Phe Ala Glu Leu Thr Gln Thr Leu Met Phe Ala Thr Gln Gln Gln
            205                 210                 215

CAG CAA CAA CAG CAA CAG CAT CAA CAG AGT GGT AGC TAT TCG CCA GAT          902
Gln Gln Gln Gln Gln Gln His Gln Gln Ser Gly Ser Tyr Ser Pro Asp
        220                 225                 230

ATT CCG AAG GCA GAT CCC GAG GAT GAC GAG GAC GAC TCA ATG GAC AAC          950
Ile Pro Lys Ala Asp Pro Glu Asp Asp Glu Asp Asp Ser Met Asp Asn
    235                 240                 245

AGC AGC ACG CTG TGC TTG CAG TTG CTC GCC AAC AGC GCC AGC AAC AAC          998
Ser Ser Thr Leu Cys Leu Gln Leu Leu Ala Asn Ser Ala Ser Asn Asn
250                 255                 260                 265

AAC TCG CAG CAC CTG AAC TTT AAT GCT GGG GAA GTA CCC ACC GCT CTG         1046
Asn Ser Gln His Leu Asn Phe Asn Ala Gly Glu Val Pro Thr Ala Leu
                270                 275                 280

CCT ACC ACC TCG ACA ATG GGG CTT ATT CAG AGT TCG CTG GAC ATG CGG         1094
Pro Thr Thr Ser Thr Met Gly Leu Ile Gln Ser Ser Leu Asp Met Arg
            285                 290                 295

GTC ATC CAC AAG GGA CTG CAG ATC CTG CAG CCC ATC CAA AAC CAA CTG         1142
Val Ile His Lys Gly Leu Gln Ile Leu Gln Pro Ile Gln Asn Gln Leu
        300                 305                 310

GAG CGA AAT GGT AAT CTG AGT GTG AAG CCC GAG TGC GAT TCA GAG GCG         1190
Glu Arg Asn Gly Asn Leu Ser Val Lys Pro Glu Cys Asp Ser Glu Ala
    315                 320                 325

GAG GAC AGT GGC ACC GAG GAT GCC GTA GAC GCG GAG CTG GAG CAC ATG         1238
Glu Asp Ser Gly Thr Glu Asp Ala Val Asp Ala Glu Leu Glu His Met
330                 335                 340                 345

GAA CTA GAC TTT GAG TGC GGT GGG AAC CGA AGC GGT GGA AGC GAT TTT         1286
Glu Leu Asp Phe Glu Cys Gly Gly Asn Arg Ser Gly Gly Ser Asp Phe
                350                 355                 360

GCT ATC AAT GAG GCG GTC TTT GAA CAG GAT CTT CTC ACC GAT GTG CAG         1334
Ala Ile Asn Glu Ala Val Phe Glu Gln Asp Leu Leu Thr Asp Val Gln
            365                 370                 375

TGT GCC TTT CAT GTG CAA CCG CCG ACT TTG GTC CAC TCG TAT TTA AAT         1382
Cys Ala Phe His Val Gln Pro Pro Thr Leu Val His Ser Tyr Leu Asn
        380                 385                 390

ATT CAT TAT GTG TGT GAG ACG GGC TCG CGA ATC ATT TTT CTC ACC ATC         1430
Ile His Tyr Val Cys Glu Thr Gly Ser Arg Ile Ile Phe Leu Thr Ile
    395                 400                 405

CAT ACC CTT CGA AAG GTT CCA GTT TTC GAA CAA TTG GAA GCC CAT ACA         1478
His Thr Leu Arg Lys Val Pro Val Phe Glu Gln Leu Glu Ala His Thr
410                 415                 420                 425
```

```
CAG GTG AAA CTC CTG AGA GGA GTG TGG CCA GCA TTA ATG GCT ATA GCT      1526
Gln Val Lys Leu Leu Arg Gly Val Trp Pro Ala Leu Met Ala Ile Ala
                430                 435                 440

TTG GCG CAG TGT CAG GGT CAG CTT TCG GTG CCC ACC ATT ATC GGG CAG      1574
Leu Ala Gln Cys Gln Gly Gln Leu Ser Val Pro Thr Ile Ile Gly Gln
            445                 450                 455

TTT ATT CAA AGC ACT CGC CAG CTA GCG GAT ATC GAT AAG ATC GAA CCG      1622
Phe Ile Gln Ser Thr Arg Gln Leu Ala Asp Ile Asp Lys Ile Glu Pro
        460                 465                 470

TTG AAG ATC TCG AAG ATG GCA AAT CTC ACC AGG ACC CTG CAC GAC TTT      1670
Leu Lys Ile Ser Lys Met Ala Asn Leu Thr Arg Thr Leu His Asp Phe
    475                 480                 485

GTC CAG GAG CTC CAG TCA CTG GAT GTT ACT GAT ATG GAG TTT GGC TTG      1718
Val Gln Glu Leu Gln Ser Leu Asp Val Thr Asp Met Glu Phe Gly Leu
490                 495                 500                 505

CTG CGT CTG ATC TTG CTC TTC AAT CCA ACG CTC TTC CAG CAT CGC AAG      1766
Leu Arg Leu Ile Leu Leu Phe Asn Pro Thr Leu Phe Gln His Arg Lys
                510                 515                 520

GAG CGG TCG TTG CGA GGC TAC GTC CGC AGA GTC CAA CTC TAC GCT CTG      1814
Glu Arg Ser Leu Arg Gly Tyr Val Arg Arg Val Gln Leu Tyr Ala Leu
            525                 530                 535

TCA AGT TTG AGA AGG CAG GGT GGC ATC GGC GGC GGC GAG GAG CGC TTT      1862
Ser Ser Leu Arg Arg Gln Gly Gly Ile Gly Gly Gly Glu Glu Arg Phe
        540                 545                 550

AAT GTT CTG GTG GCT CGC CTT CTT CCG CTC AGC AGC CTG GAC GCA GAG      1910
Asn Val Leu Val Ala Arg Leu Leu Pro Leu Ser Ser Leu Asp Ala Glu
    555                 560                 565

GCC ATG GAG GAG CTG TTC TTC GCC AAC TTG GTG GGG CAG ATG CAG ATG      1958
Ala Met Glu Glu Leu Phe Phe Ala Asn Leu Val Gly Gln Met Gln Met
570                 575                 580                 585

GAT GCT CTT ATT CCG TTC ATA CTG ATG ACC AGC AAC ACC AGT GGA CTG      2006
Asp Ala Leu Ile Pro Phe Ile Leu Met Thr Ser Asn Thr Ser Gly Leu
                590                 595                 600

TAGGCGGAAT TGAGAAGAAC AGGGCGCAAG CAGATTCGCT AGACTGCCCA AAAGCAAGAC    2066

TGAAGATGGA CCAAGTGCGG GCAATACATG TAGCAACTAG GCAAATCCCA TTAATTATAT    2126

ATTTAATATA TACAATATAT AGTTTAGGAT ACAATATTCT AACATAAAAC CATGAGTTTA    2186

TTGTTGTTCA CAGATAAAAT GGAATCGATT TCCCAATAAA AGCGAATATG TTTTTAAACA    2246

GAATGTTTGC ATCAGAACTT TGAGATGTAT ACATTAGATT ATTACAACAC AAAAAAAAAA    2306

AAAAAAAAA                                                            2315
```

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 601 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```
Met Asp Gly Val Lys Val Glu Thr Phe Ile Lys Ser Glu Glu Asn Arg
 1               5                  10                  15

Ala Met Pro Leu Ile Gly Gly Gly Ser Ala Ser Gly Gly Thr Pro Leu
            20                  25                  30

Pro Gly Gly Gly Val Gly Met Gly Ala Gly Ala Ser Ala Thr Leu Ser
        35                  40                  45

Val Glu Leu Cys Leu Val Cys Gly Asp Arg Ala Ser Gly Arg His Tyr
    50                  55                  60

Gly Ala Ile Ser Cys Glu Gly Cys Lys Gly Phe Phe Lys Arg Ser Ile
65                  70                  75                  80

Arg Lys Gln Leu Gly Tyr Gln Cys Arg Gly Ala Met Asn Cys Glu Val
                85                  90                  95

Thr Lys His His Arg Asn Arg Cys Gln Phe Cys Arg Leu Gln Lys Cys
            100                 105                 110

Leu Ala Ser Gly Met Arg Ser Asp Ser Val Gln His Glu Arg Lys Pro
        115                 120                 125

Ile Val Asp Arg Lys Glu Gly Ile Ile Ala Ala Ala Gly Ser Ser Ser
    130                 135                 140

Thr Ser Gly Gly Gly Asn Gly Ser Ser Thr Tyr Leu Ser Gly Lys Ser
145                 150                 155                 160

Gly Tyr Gln Gln Gly Arg Gly Lys Gly His Ser Val Lys Ala Glu Ser
                165                 170                 175

Ala Pro Arg Leu Gln Cys Thr Ala Arg Gln Gln Arg Ala Phe Asn Leu
            180                 185                 190

Asn Ala Glu Tyr Ile Pro Met Gly Leu Asn Phe Ala Glu Leu Thr Gln
        195                 200                 205

Thr Leu Met Phe Ala Thr Gln Gln Gln Gln Gln Gln Gln Gln His
    210                 215                 220

Gln Gln Ser Gly Ser Tyr Ser Pro Asp Ile Pro Lys Ala Asp Pro Glu
225                 230                 235                 240

Asp Asp Glu Asp Asp Ser Met Asp Asn Ser Ser Thr Leu Cys Leu Gln
                245                 250                 255

Leu Leu Ala Asn Ser Ala Ser Asn Asn Asn Ser Gln His Leu Asn Phe
            260                 265                 270

Asn Ala Gly Glu Val Pro Thr Ala Leu Pro Thr Thr Ser Thr Met Gly
        275                 280                 285

Leu Ile Gln Ser Ser Leu Asp Met Arg Val Ile His Lys Gly Leu Gln
    290                 295                 300
```

Ile Leu Gln Pro Ile Gln Asn Gln Leu Glu Arg Asn Gly Asn Leu Ser
305 310 315 320

Val Lys Pro Glu Cys Asp Ser Glu Ala Glu Asp Ser Gly Thr Glu Asp
325 330 335

Ala Val Asp Ala Glu Leu Glu His Met Glu Leu Asp Phe Glu Cys Gly
340 345 350

Gly Asn Arg Ser Gly Gly Ser Asp Phe Ala Ile Asn Glu Ala Val Phe
355 360 365

Glu Gln Asp Leu Leu Thr Asp Val Gln Cys Ala Phe His Val Gln Pro
370 375 380

Pro Thr Leu Val His Ser Tyr Leu Asn Ile His Tyr Val Cys Glu Thr
385 390 395 400

Gly Ser Arg Ile Ile Phe Leu Thr Ile His Thr Leu Arg Lys Val Pro
405 410 415

Val Phe Glu Gln Leu Glu Ala His Thr Gln Val Lys Leu Leu Arg Gly
420 425 430

Val Trp Pro Ala Leu Met Ala Ile Ala Leu Ala Gln Cys Gln Gly Gln
435 440 445

Leu Ser Val Pro Thr Ile Ile Gly Gln Phe Ile Gln Ser Thr Arg Gln
450 455 460

Leu Ala Asp Ile Asp Lys Ile Glu Pro Leu Lys Ile Ser Lys Met Ala
465 470 475 480

Asn Leu Thr Arg Thr Leu His Asp Phe Val Gln Glu Leu Gln Ser Leu
485 490 495

Asp Val Thr Asp Met Glu Phe Gly Leu Leu Arg Leu Ile Leu Leu Phe
500 505 510

Asn Pro Thr Leu Phe Gln His Arg Lys Glu Arg Ser Leu Arg Gly Tyr
515 520 525

Val Arg Arg Val Gln Leu Tyr Ala Leu Ser Ser Leu Arg Arg Gln Gly
530 535 540

Gly Ile Gly Gly Gly Glu Glu Arg Phe Asn Val Leu Val Ala Arg Leu
545 550 555 560

Leu Pro Leu Ser Ser Leu Asp Ala Glu Ala Met Glu Glu Leu Phe Phe
565 570 575

Ala Asn Leu Val Gly Gln Met Gln Met Asp Ala Leu Ile Pro Phe Ile
580 585 590

Leu Met Thr Ser Asn Thr Ser Gly Leu
595 600

That which is claimed is:

1. DNA encoding a polypeptide characterized by having a DNA binding domain comprising about 66 amino acids with 9 Cys residues, wherein said DNA binding domain has:

(i) less than about 70% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) less than about 60% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) less than about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) less than about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

2. DNA according to Claim 1 wherein the ligand binding domain of said polypeptide has:

(i) less than about 35% amino acid sequence identity with the ligand binding domain of hRAR-alpha;

(ii) less than about 30% amino acid sequence identity with the ligand binding domain of hTR-beta;

(iii) less than about 25% amino acid sequence identity with the ligand binding domain of hGR; and

(iv) less than about 30% amino acid sequence identity with the ligand binding domain of hRXR-alpha.

3. DNA according to Claim 1 wherein said polypeptide has an overall amino acid sequence identity of:

(i) less than about 35% relative to hRAR-alpha;

(ii) less than about 35% relative to hTR-beta;

(iii) less than about 25% relative to hGR; and

(iv) less than about 35% relative to hRXR-alpha.

4. DNA according to Claim 1 wherein said polypeptide is characterized by having a DNA binding domain comprising **[XR1]**:

(i) about 68% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 59% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 45% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

5. DNA according to Claim 1 wherein said polypeptide is characterized by having a DNA binding domain comprising **[XR2]**:

(i) about 55% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 56% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 52% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

6. DNA according to Claim 1 wherein said polypeptide is characterized by having a DNA binding domain comprising [XR4]:

(i) about 62% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 58% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 48% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 62% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

7. DNA according to Claim 1 wherein said polypeptide is characterized by having a DNA binding domain comprising [XR5]:

(i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 52% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 44% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 61% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

8. DNA according to Claim 1 wherein said polypeptide is characterized by having a DNA binding domain comprising [XR79]:

(i) about 59% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) about 55% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

9. DNA according to Claim 1 wherein the nucleotide sequence of said DNA is selected from the nucleotide sequence set forth in Sequence ID No. 1, the combination of Sequence ID No. 3 and the continuation thereof as set forth in Sequence ID No. 1, the combination of Sequence ID No. 5 and the continuation thereof as set forth in Sequence ID No. 1, Sequence ID No. 7, Sequence ID No. 9, Sequence ID No. 11, or Sequence ID No. 13.

10. An expression vector comprising DNA according to claim 1, and further comprising:

at the 5'-end of said DNA, a promoter and a triplet encoding a translational start codon, and

at the 3'-end of said DNA, a triplet encoding a translational stop codon;

wherein said expression vector is operative in an animal cell in culture to express the protein encoded by the continuous sequence of amino acid-encoding triplets.

11. An animal cell in culture transformed with an expression vector according to Claim 10.

12. A method of making a polypeptide comprising culturing the cells of Claim 11 under conditions suitable for the expression of said polypeptide.

13. The polypeptide produced by the method of Claim 12.

14. A polypeptide characterized by having a DNA binding domain comprising about 66 amino acids with 9 Cys residues, wherein said DNA binding domain has:

(i) less than about 70% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) less than about 60% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) less than about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) less than about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha.

15. A DNA or RNA labeled for detection; wherein said DNA or RNA comprises a nucleic acid segment of at least 20 bases in length, wherein said segment has substantially the same sequence as a segment of the same length selected from the DNA segment represented by bases 21 -1902, inclusive, of Sequence ID No. 1, bases 1 - 386, inclusive, of Sequence ID No. 3, bases 10 - 300, inclusive, of Sequence ID No. 5, bases 21 - 1615, inclusive, of Sequence ID No. 7, bases 21 - 2000, inclusive, of Sequence ID No. 9, bases 1 - 2450, inclusive, of Sequence ID No. 11, bases 21 - 2295, inclusive, of Sequence ID No. 13, or the complement of any one of said segments.

16. A method of testing a compound for its ability to regulate transcription-activating effects of a receptor polypeptide, said method comprising assaying for the presence or absence of reporter protein upon contacting of cells containing a receptor polypeptide and reporter vector with said compound;

wherein said receptor polypeptide is characterized by having a DNA binding domain comprising about 66 amino acids with 9 Cys residues, wherein said DNA binding domain has:

(i) less than about 70% amino acid sequence identity with the DNA binding domain of hRAR-alpha;

(ii) less than about 60% amino acid sequence identity with the DNA binding domain of hTR-beta;

(iii) less than about 50% amino acid sequence identity with the DNA binding domain of hGR; and

(iv) less than about 65% amino acid sequence identity with the DNA binding domain of hRXR-alpha; and

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element, and

(c) a DNA segment encoding a reporter protein,

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof.

17. A chimeric receptor comprising at least an amino-terminal domain, a DNA-binding domain, and a ligand-binding domain,

wherein at least one of the domains thereof is derived from the polypeptide of Claim 13; and

wherein at least one of the domains thereof is derived from at least one previously identified member of the steroid/thyroid superfamily of receptors.

18. DNA encoding the chimeric receptor of Claim 17.

19. A method to identify compounds which act as ligands for receptor polypeptides according to Claim 13 comprising:

assaying for the presence or absence of reporter protein upon contacting of cells containing a chimeric form of said receptor polypeptide and reporter vector with said compound;

wherein said chimeric form of said receptor polypeptide comprises the ligand binding domain of said receptor polypeptide and the amino-terminal and DNA-binding domains of at least one previously identified member of the steroid/thyroid superfamily of receptors;

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element which is responsive to the receptor from which the DNA-binding domain of said chimeric form of said receptor polypeptide is derived, and

(c) a DNA segment encoding a reporter protein,

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof, and thereafter

selecting those compounds which induce or block the production of reporter in the presence of said chimeric form of said receptor polypeptide.

20. A method to identify response elements for receptor polypeptides according to Claim 13 comprising:

assaying for the presence or absence of reporter protein upon contacting of cells containing a chimeric form of said receptor polypeptide and reporter vector with a compound which is a known agonist or antagonist for the receptor from which the ligand-binding domain of said chimeric form of said receptor polypeptide is derived;

wherein said chimeric form of said receptor polypeptide comprises the DNA-binding domain of the receptor polypeptide and the amino-terminal and ligand-binding domains of at least one previously identified member of the steroid/thyroid superfamily of receptors;

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a putative hormone response element, and

(c) a DNA segment encoding a reporter protein,

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof; and

identifying those response elements for which the production of reporter is induced or blocked in the presence of said chimeric form of said receptor polypeptide.

21. A method of testing a compound for its ability to selectively regulate transcription-activating effects of a specific receptor polypeptide, said method comprising:

assaying for the presence or absence of reporter protein upon contacting of cells containing said receptor polypeptide and reporter vector with said compound;

wherein said receptor polypeptide is characterized by being responsive to the presence of a known ligand for said receptor to regulate the transcription of associated gene(s);

wherein said reporter vector comprises:

(a) a promoter that is operable in said cell,

(b) a hormone response element, and

(c) a DNA segment encoding a reporter protein,

wherein said reporter protein-encoding DNA segment is operatively linked to said promoter for transcription of said DNA segment, and

wherein said hormone response element is operatively linked to said promoter for activation thereof; and

assaying for the presence or absence of reporter protein upon contacting of cells containing chimeric receptor polypeptide and reporter vector with said compound;

wherein said chimeric receptor polypeptide comprises the ligand binding domain of the receptor of Claim 13 and the DNA binding domain of said specific receptor; and thereafter

selecting those compounds which induce or block the production of reporter in the presence of said specific receptor, but are substantially unable to induce or block the production of reporter in the presence of said chimeric receptor.

22. A method according to Claim 21 wherein said contacting is carried out in the further presence of at least one agonist for said specific receptor.


verht19
1
1952
349
352
verht3
1
1952
383
349
verhr5
1
1952
300
352

FIG. 1

INTERNATIONAL SEARCH REPORT

PCT/US 92/07570

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)[6]

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C12N15/12; C12N15/62; C07K13/00; C12N5/10
C12Q1/68; C07K15/00

II. FIELDS SEARCHED

Minimum Documentation Searched[7]

Classification System	Classification Symbols
Int.Cl. 5	C12N ; C07K ; C12Q

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched[8]

III. DOCUMENTS CONSIDERED TO BE RELEVANT[9]

Category °	Citation of Document,[11] with indication, where appropriate, of the relevant passages[12]	Relevant to Claim No.[13]
Y	WO,A,9 113 167 (LELAND STANFORD JUNIOR UNIVERSITY, US) 5 September 1991 See Page 67, Table 4 page 111, claims	1-8, 10-22
Y	WO,A,9 112 258 (THE SALK INST. FOR BIOL. STUDIES, US) 22 August 1991 See Figure 1, claims	1-8, 10-22
Y	WO,A,9 006 364 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, US) 14 June 1990 see the whole document	1-8, 10-20

° Special categories of cited documents :[10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
17 DECEMBER 1992	21.01.93
International Searching Authority	**Signature of Authorized Officer**
EUROPEAN PATENT OFFICE	S.A. NAUCHE

Form PCT/ISA/210 (second sheet) (January 1985)

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. US 9207570 SA 64632

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 17/12/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9113167	05-09-91	AU-A-	7492291	18-09-91
		EP-A-	0517805	16-12-92
WO-A-9112258	22-08-91	AU-A-	7338391	03-09-91
		EP-A-	0514488	25-11-92
WO-A-9006364	14-06-90	AU-A-	4809090	26-06-90
		CA-A-	2003996	31-05-90
		EP-A-	0457766	27-11-91
		JP-T-	4502320	23-04-92